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ABSTRACT 
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like editing complex 3G 
(APOBEC3G) is a DNA editing enzyme that deaminates deoxycytidines, converting them to 
deoxyuridines. APOBEC3G hypermutates human immunodeficiency virus type 1 (HIV-1) DNA 
during reverse transcription, resulting in the inhibition of viral propagation. The HIV-1 accessory 
protein named viral infectivity factor (Vif) counteracts the antiviral action of A3G by targeting it 
for degradation. The objective of this work is to evaluate whether the inhibitory effect of Vif on 
A3G can be diminished by pokeweed antiviral protein (PAP) and to determine the effect of PAP 
on HIV-1 infectivity and viral production. PAP is an N-glycosidase synthesized by the pokeweed 
plant, Phytolacca americana. It was previously shown that PAP exhibits antiviral activity against 
a broad range of plant and animal viruses, including HIV-1, at concentrations that are not toxic to 
the cells. In this study, I show that expression of PAP in cells reduced Vif protein accumulation 
by depurinating Vif open reading frame (ORF). Decreased Vif protein levels in the presence of 
PAP were correlated with increased A3G levels in HeLa cells stably expressing A3G. The 
antiviral enzyme reduced viral particle release by approximately 100-fold and the virions 
released from PAP expressing cells were 11-fold less infectious compared to virions released 
from PAPx expressing cells, an active site mutant lacking catalytic activity. The expression of 
PAP in producer HeLa-A3G cells reduced the levels of HIV-1 proviral DNA in target Jurkat 
cells. Downregulation of Vif by PAP and its effect on A3G is a novel finding, suggesting that 
PAP enhances the cellular innate immunity against HIV-1 by inhibiting Vif protein expression. 
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1. INTRODUCTION 
1.1 APOBEC family of enzymes 
1.1.1 General characteristics 
Apolipoprotein B messenger RNA (mRNA)-editing enzyme catalytic polypeptide-like 
editing complex (APOBEC) family of proteins consists of 11 members in humans: activation-
induced cytidine deaminase (AID), APOBEC1 (A1), APOBEC2 (A2), APOBEC3 (A3: A3A, 
A3B, A3C, A3DE, A3F, A3G, A3H), and APOBEC4 (A4). All members of APOBEC family of 
proteins act as cytidine deaminases, converting cytidines to uridines in RNA or deoxycytosines 
to deoxyuridines in single-stranded DNA (ssDNA) substrates (Pathak et al. 2014, Smith et al. 
2012). This enzymatic activity is achieved with zinc-dependent cytidine or deoxycytidine 
deaminase domain (ZDD) organized as HXEX23-28-PCX2-4C, which allows the removal of 
exocyclic amine (Jarmuz et al. 2002, Wedekind et al. 2003). The zinc ion is coordinated by 
histidine and two cysteine residues located within ZDD (Smith et al. 2012). Glutamic acid is 
important for the deaminase activity by shuttling protons in the active site (Jarmuz et al. 2002). 
AID, A1, A3A, A3C and A3H contain one deaminase domain, while A3B, A3DE, A3F and A3G 
have two ZDDs (Wedekind et al. 2003, Smith et al. 2012, Jarmuz et al. 2002). Of the members 
with two ZDDs, the C-terminal ZDD has enzymatic activity, while the N-terminal Zn domain 
has high affinity for RNA-binding (Zheng et al. 2012). The second ZDD could have arisen by 
tandem duplication of the ancestral gene. Beside the conserved ZDD, all members share at least 
one active site cluster, a linker region and pseudoactive site domain (Hamilton et al. 2010). The 
schematic of APOBEC domain organization is illustrated in Figure 1.  
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Figure 1. Schematic of APOBEC proteins’ domain organization. All members of the family 
share conserved zinc deaminase domain (ZDD). While AID, A1, A3A, A3C and A3H contain 
one ZDD, A3B, A3DE, A3F and A3G have two ZDDs. The active site domain is joined by a 
linker to pseudo-active site. 
 
1.1.2 Family members 
A1 was the first mammalian cytidine deaminase identified as an enzyme that edits 
apolipoprotein B (apo B) pre-mRNA (Naratnam et al. 1993, Teng et al. 1993). Two versions of 
apoB proteins were found in human liver and intestine and this polymorphism was attributed to 
posttranscriptional RNA editing (Chen et al. 1987). Deamination of a specific cytidine (C6666) 
by A1 introduces a premature translation stop codon (UAA), resulting in a truncated apoB 
protein. This apoB protein variant plays an important role in lipid metabolism (Teng et al 1993, 
Navaratnam et al. 1993). The function of AID was discovered through subtractive hybridization 
screen that compared transcripts between resting and activated B cells undergoing 
immunoglobulin gene diversification (Muramatsu et al. 1999). AID is required for somatic 
hypermutation and class-switch recombination of immunoglubin genes and therefore antibody 
diversification (Muramatsu et al. 2000, Arakawa et al. 2002). A2 is expressed in skeletal and 
cardiac muscle where it was shown to play a role in muscle differentiation and maintenance of 
fiber-type ratios (Sato et al. 2010, Vonica et al. 2010, Etard et al. 2010). A2 also contributes to 
specification of left-right axis symmetry by regulating transforming growth factor β (TGFβ) 
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signalling during embryogenesis (Vonica et al. 2010). A4 is expressed in testes, but its function 
is unknown (Rogozin et al. 2005).   
1.1.3 APOBEC3 enzymes 
The discovery of APOBEC3 enzymes as inhibitors of retroviruses came from initially 
unrelated work in the field of HIV-1 studies. Research on HIV-1 revealed that mutants lacking a 
gene encoding the accessory protein viral infectivity factor (Vif) were unable to replicate in 
primary CD4+ T cells and macrophages, as well as some T-cell leukemia cell lines (e.g., CEM 
and H9 cells) (Gabuzda et al. 1992, Sakai et al. 1993).  These cell lines were termed non-
permissive since vif-deficient HIV-1 (HIV-1Δvif) could not be propagated in them. In contrast, 
HIV-1Δvif mutants were able to be propagated in permissive cell lines including all adherent 
cells (e.g., HEK293T and HeLa) and some T-cell lines (e.g., CEM-SS and SupT1). Fusion of 
non-permissive and permissive cells to create a heterokaryon revealed that the non-permissive 
phenotype was dominant (Simon et al. 1998). This suggested that a factor present in non-
permissive cell lines was blocking replication of HIV-1Δvif. cDNA subtraction between 
permissive and non-permissive cells identified APOBEC3G (A3G) as the restriction factor 
(Sheehy et al. 2002). Transfection of a construct encoding a functional A3G protein was 
sufficient to convert permissive phenotype to non-permissive (Sheehy et al. 2002). Therefore, 
A3G was identified as the factor that inhibits the propagation of HIV-1Δvif in non-permissive 
cell lines.   
Since the discovery of A3G as an HIV-1 restriction factor, A3 family of proteins has been 
intensely studied. The human A3 locus is located on chromosome 22 in humans (Jarmuz et al. 
2002). While humans have 7 A3 genes, rodents, cats, pigs and sheep have only one A3 gene. 
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Two A3 genes are found in cows and 3 in dogs and horses (Smith et al. 2012). A3 proteins share 
approximately 50% sequence homology at the amino acid level (Cullen 2006). A3 enzymes are 
thought to function as components of innate immunity, to limit mobile genetic elements in the 
form of endogenous retroelements and exogenous viruses (Chiu et al. 2005, Peng et al. 2007, 
Koning et al. 2009, Reflsland et al. 2010, Esnault et al. 2006). Integration of retrotransposons 
may affect genetic stability by causing DNA deletions, insertions and rearrangements (Arias et 
al. 2012). Therefore, it is thought that A3 genes have expanded in primates to limit the 
retrotransposition of these mobile elements and infection of modern lentiviruses (Hamilton et al. 
2010, Monameji et al. 2012). This is supported by the observed correlation between expansion of 
the A3 gene cluster and dramatic reduction in retrotransposition activity (Sawyer et al. 2004). 
Besides HIV-1, other exogenous viruses were shown to be targeted by A3 members, including 
human T cell leukemia virus type 1 (HTLV-1) (Sasada et al. 2005, Fan et al. 2010), hepatitis B 
virus (HBV) (Turelli et al. 2004), and human papillomavirus (HPV) (Vartanian et al. 2008).  
Therefore, A3 proteins can act as potent inhibitors of both, endogenous retroelements to protect 
genetic integrity, and exogenous viruses to enhance innate immunity.  
Although A3G is the most well characterized member of the A3 family, other members, 
including A3F and A3DE have also been shown to target and inhibit the replication of HIV-1 
and other retroviruses, although to a lesser extent (Bishop et al. 2004, Rose et al. 2005, Hulquist 
et al. 2011, Zielonka et al. 2009). Besides A3G, A3F is the second most potent suppressor of 
HIV-1 Vif. A3F recognizes different target sequence compared to A3G (Bishop et al. 2004, 
Liddament et al. 2004). Whereas A3G has a preference for dCC sequences, A3F preferentially 
deaminates TC targets (Liddament et al. 2004, Bishop et al. 2004).   
 
5 
 
1.2 APOBEC3G 
1.2.1 A3G activity 
A3G is the most well characterized and studied member of the APOBEC family due to its 
potent anti-HIV-1 activity. A3G is primarily expressed in CD4+ T lymphocytes and 
macrophages (Chiu et al. 2005, Peng et al. 2007, Koning et al. 2009, Reflsland et al. 2010). A3G 
is packaged into HIV-1Δvif virions, which allows its close proximity to viral RNA and reverse 
transcription complex (Alce et al. 2004, Cen et al. 2004, Luo et al. 2004, Svarovskaia et al. 2004, 
Khan et al. 2004). After infection of susceptible cells, A3G mutates the viral genome during 
reverse transcription when the viral RNA is being transcribed into cDNA (Figure 2). A3G 
deaminates deoxycytosines into deoxyuridines in the minus-strand cDNA (Harris et al. 2003, 
Mangeat et al. 2003, Zhang et al. 2003). This editing activity of A3G is very efficient, resulting 
in up to 20% of all minus-strand dC residues being converted to dU residues (Cullen 2006). The 
editing occurs in graded frequency in the 5’ to 3’ direction across the HIV-1 genome; the regions 
of the genome that are reverse transcribed first are mutated the most (Yu et al. 2004).  Since A3G 
targets ssDNA templates, it is the minus-strand DNA that gets edited because only the minus-
strand proceeds through a transient single-stranded phase during reverse transcription. The 
graded frequency of deamination is caused by the differences in time that regions of the genome 
remain single-stranded (Yu et al. 2004a).  
The introduction of deoxyuridines not normally found in DNA was hypothesized to 
attract DNA glycosylases and apurinic-apuyrimidinic endonucleases, resulting in degradation of 
viral cDNA (Schrofelbauer et al. 2005, Yang et al. 2007). Therefore, the observed decrease in the 
accumulation of viral reverse transcripts (Mariani et al. 2003, Mangeat et al. 2003, Iwatani et  
 
6 
 
 
         
 
Figure 2. A3G restricts HIV-1Δvif  infection. Upon infection of a susceptible cell, A3G is 
released from vif-deficient HIV-1 virions. During reverse transcription of the HIV-1 RNA, A3G 
deaminates deoxycytosines in the minus-strand DNA, converting them into deoxyuracils. This in 
turn leads to deoxyguanine to deoxyadenine convertions in plus-strand DNA. Editing activity of 
A3G results in decreased reverse transcript accumulation and inhibition of proviral DNA 
integration. The integrated hypermutated HIV-1 DNA is largely defective due to introduction of 
premature stop codons and substitution mutations. Adapted from Desimmie et al. 2014.  
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al. 2007, Bishop et al. 2008) in the presence of A3G may be attributed to the action of DNA 
repair enzymes. However, this remains elusive as inhibition of uracil DNA glycosidases did not 
reverse A3G effect on HIV-1 cDNA levels (Langlois and Nauberger 2008). 
Additionally, the editing activity of A3G causes deoxyguanine (dG) to deoxyadenosine 
(dA) conversions in the plus-strand cDNA, resulting in substitution mutations and premature 
translation stop codons that could cause a loss of genetic integrity (Harris et al. 2003, Mangeat et 
al. 2003, Yu et al. 2004, Zhang et al. 2003, Lecossier et al. 2003). A3G is also able to function 
through cytidine deamination-independent mechanisms by blocking different steps of reverse 
transcription, including annealing of the primer to viral RNA template, restricting DNA strand 
transfer, inhibiting elongation of reverse transcription and obstructing viral integration (Bishop et 
al. 2008, Newman et al. 2005, Mbisa et al. 2007, Li et al. 2007, Luo et al. 2007, Guo et al. 2007, 
Wang et al. 2012). The mechanism of HIV-1Δvif restriction by A3G is illustrated in Figure 2.  
1.2.2 Intravirion packaging of A3G 
In the absence of Vif, A3G gets packaged into viral particles through its interaction with 
the nucleocapsid (NC) portion of the Gag polyprotein in RNA-dependent manner (Alce and 
Popik 2004, Cen et al. 2004, Khan et al. 2005, Luo et al. 2004, Schäfer et al. 2004, Svarovskaia 
et al. 2004, Zennou et al. 2004). The virion-packaged fraction of A3G is responsible for viral 
restriction in target cells and the number of A3G molecules packaged into virions depends on its 
cytosolic levels in the producer cell (Svarovskaia et al. 2004, Alce and Popik 2004, Xu et al. 
2007). Virus particles released from peripheral blood mononuclear cells (PBMCs) were shown to 
contain approximately 3-11 molecules of A3G, which was effective for viral restriction (Xu et al. 
2007). Using stochastic simulations and mathematical modelling, it was estimated that about 
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80% of progeny virions need to incorporate A3G in order to render HIV-1 infection 
unsustainable (Thangavelu et al. 2014). Therefore, the interplay between Vif and A3G modulates 
virus propagation. That is, high levels of A3G would increase viral DNA mutation load to 
significantly inhibit virus production, whereas low levels of A3G could potentially provide a 
selective advantage for the virus through non-lethal mutation rates that generate variants with 
increased fitness, such as drug resistance and the ability to escape from adaptive immune system 
(Simon et al. 2005, Sadler et al. 2010, Wood et al. 2009, Berkhout and deRonde 2004, Smith 
2011). Therefore, complete inhibition of Vif activity might be required in order to prevent 
generation of virus variation and drug resistant strains arising from limited editing by A3G and 
must be considered in a design of new therapeutic approaches. 
Some studies performed on HIV-1 infected patients showed inverse correlation between 
A3G expression levels and disease progression (Kourteva et al. 2012, Eyzaguirre et al. 2013, 
Ulenga et al. 2008, Jin et al. 2005). Long-term non-progressors (LTNPs) had higher A3G and 
A3F mRNA levels, lower virus burden and higher amount of hypermutated HIV-1 proviral DNA 
(Kourteva et al. 2012, Jin et al. 2005). Most of the defective HIV-1 genomes in LTNPs were 
caused by G to A hypermutation (Eyzaguirre et al. 2013). However, other studies showed no 
correlation between disease progression and A3G expression (Gandhi et al. 2008a). Thus, 
association between the ability to control viremia and A3G expression in vivo remains unclear.  
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1.3 Human Immunodeficiency virus type 1 (HIV-1) 
1.3.1 General Characteristics 
Human immunodeficiency virus type 1 (HIV-1) belongs to the Lentivirus genus of the 
Retroviridae family of viruses (Levy 1993). Retroviruses are enveloped viruses that contain 
virally encoded reverse transcriptase (RT) that converts the RNA genome into DNA during the 
process of reverse transcription. The members of the Lentivirus genus are associated with slow 
progression of disease (Levy 1993). HIV-1 was identified to be the causative agent of acquired 
immunodeficiency syndrome (AIDS) in 1983 by Luc Montagnier and Barre-Sinoussi (Barrè-
Sinoussi et al. 1983). Since its discovery over 30 years ago, HIV-1 has infected over 60 million 
people and caused more than 25 million deaths (Merson et al. 2008). Therefore, HIV-1 has 
caused a major global pandemic, causing the highest mortality rates in developing countries 
including sub-Saharan Africa and South-East Asia.  
 HIV-1 is spread by sexual, percutaneous and intravenous routes, although 80% of all 
infections are sexually transmitted (Cohen et al. 2011). Once transmitted across the mucosal 
membrane, HIV-1 infects CD4+ T cells (helper T cells) and macrophages. The primary receptor 
is CD4 antigen present on the surface of both macrophages and CD4+ T cells. The virus also 
requires a co-receptor which is a chemokine receptor CCR5 or CXCR4 present on macrophages 
and T cells, respectively. During the acute infection, which occurs 4-6 weeks following the 
exposure to the virus, HIV-1 is rapidly expanded in gut-associated lymphoid tissue (GALT) and 
systematically, resulting in a sharp decline in helper T cells reservoirs (Cohen et al. 2011). The 
acute infection resolves and latency period of 8-10 years, characterized by clearance of the virus 
from circulation and replication in lymph nodes, follows (Cohen et al. 2011). During the latency 
period, there is a gradual depletion of CD4+ T cells which eventually results in acquired 
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immunodeficiency syndrome (AIDS). Patients suffer from wide range of opportunistic infections 
and malignancies such as sarcomas, lymphomas and neurological disorders due to compromised 
immune system (Levy 1993). The introduction of highly active antiretroviral therapy (HAART), 
which relies on a combination of drugs targeting different steps of viral replication, has 
dramatically improved the clinical outcome and life expectancy (Barrè-Sinousii et al. 2013). 
However, the drug therapy does not eradicate the virus and drug resistance, side effects and viral 
latency remain some of the difficulties associated with the present treatment (Barrè-Sinousii et 
al. 2013, Passaes and Sáez-Cirión 2014).  
1.3.2 HIV-1 Structure and Genome Organization 
HIV-1 is an enveloped virus with conical capsid enclosing 2 copies of the 9-kb RNA 
genome. Within the envelope, there are viral surface protein (SU, gp120) and transmembrane 
protein (TM, gp41) that are non-covalently attached. Matrix protein (MA, p17) lines the inner 
layer of the envelope. The conical capsid is made out of the virally encoded capsid protein (CA, 
p24). Inside the capsid, the viral RNA genome is coated with nucleocapsid (NC) protein. Virally 
encoded enzymes reverse transcriptase (RT), integrase (IN), and protease (PR) are present inside 
the virion. In addition, some accessory and regulatory proteins are packaged into the virion, 
including virion protein R (Vpr) and viral infectivity factor (Vif). 
The HIV-1 genome is a plus-strand 9-kb RNA. Three genes common to all retroviruses 
are present: gag (group-specific antigen), pol (polymerases) and env (envelope proteins). gag 
encodes MA, NC and CA, pol encodes the viral enzymes PR, RT and IN and env encodes 
structural proteins SU and TM. In addition to the standard gag, pol and env genes, HIV-1 
contains 6 additional open reading frames (ORFs) encoding regulatory proteins transactivator of 
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transcription (Tat) and regulator of expression of virion proteins (Rev) and accessory proteins  
negative effector (Nef), viral infectivity factor (Vif), virion protein R (Vpr) and virion protein 
unique to HIV-1 (Vpu). The schematic of HIV-1 genome organization is illustrated in Figure 3.  
1.3.3 HIV-1 Life Cycle 
HIV-1 infects CD4+ T cells and macrophages. SU (gp120) protein binds to CD4 receptor 
and CCR5 or CXCR4 co-receptor, which generates conformational changes that allow fusion of 
the viral envelope with the cell membrane (Stein 1987). Following the fusion, viral capsid is 
released into the cytosol and viral RNA is reverse transcribed by the RT enzyme to generate 
double-stranded proviral DNA. HIV-1 DNA along with IN and other proteins form a pre-
integration complex (PIC) that allow translocation of the viral DNA into the nucleus (Arhel 
2010). HIV-1 DNA is integrated into host chromosomal DNA by IN. Long terminal repeats 
(LTRs) are found on both ends of proviral DNA; 5’ LTR serves as a promoter while 3’ LTR 
plays a role in 3’ processing of the viral RNA (Cullen 1991). Transcription from the 5’ LTR 
generates full-length 9-kb RNA which encodes Gag and Gag/Pol polyproteins (Figure 3). The 
polyproteins are later processed by viral PR to generate the structural proteins and viral enzymes. 
Single splicing of the 9-kb transcript generates 4-kb class of RNAs from which Vif, Vpr, Vpu 
and Env are expressed. In addition, the RNAs can be further spliced to yield 2-kb class of RNAs 
that encode Tat, Rev and Nef (Levy 1993, Purcel and Martin 1993). Presence of multiple splice 
sites generates over 40 different mRNAs (Tazi et al. 2010).   
Only the 2-kb class of RNAs can be transported out of the nucleus due to inhibitory cis-
acting repressive sequences (CRS) present in 4-kb and 9-kb transcripts that are spliced out in 2-
kb class of RNAs (Zhang et al. 1996). Therefore, the 9-kb and 4-kb RNAs are retained in the 
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Figure 3. HIV-1 genome organization and processing. HIV-1 proviral DNA is transcribed to 
generate full-length 9-kb transcript from which Gag and Gag/Pol polyproteins are expressed. A 
single splicing event generates the 4-kb class of RNAs that encode Vif, Vpr, Vpu and Env. 
RNAs can be further spliced to make the 2-kb class of RNAs from which Tat, Rev and Nef are 
expressed. 
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nucleus until Rev is expressed, which then allows export of these transcripts into the cytosol 
(Pollard and Malim 1998). Viral RNAs are translated in the cytosol to generate the structural and 
regulatory proteins which then assemble to form new immature virus particles (Gottfredsson et 
al. 1997). These new virus particles bud off and proteolytic processing by PR allows their 
maturation and generation of infectious virions (Gottfredsson and Bohjanen 1997). The 
schematic of the HIV-1 life-cycle is shown in Figure 4.  
 
1.4 Viral infectivity factor (Vif) 
Vif is a 23 kDa protein encoded by the 4-kb class of HIV-1 RNAs. Vif’s primary role is to target 
A3G for degradation and therefore counteract the antiviral activity of A3G. Vif interacts with E3 
ubiquitin ligase complex consisting of Elongin B, Elongin C, Cullin 5 and Rbx 1 and hijacks it to 
mediate A3G polyubiquitination and subsequent degradation by the proteasome (Yu et al. 2003, 
Marin et al. 2003, Mehle et al. 2004, Sheehy et al. 2003, Stopak et al. 2003). In addition, the 
transcription factor CBF-β was shown to be recruited to this complex and be required for Vif-
mediated degradation of A3G (Harris et al. 2011, Zhang et al. 2011). The amino acids residues 
required for the interaction between individual proteins and the assembly of the complex have 
been identified. The C-terminal of Vif contains a highly conserved suppressor of cytokine 
signalling (SOCS) motif which is required for the interaction with Elongin C (Yu et al. 2004b). 
Vif binds to Cullin 5 through a zinc-binding motif (Yu et al. 2004b). The interaction between Vif 
and A3G is species-specific and maps to a single amino acid D128 in A3G (Bogerd et al. 2004, 
Mangeat et al. 2004, Huthoff and Malim 2007). The schematic diagram of Vif interaction with 
A3G and the E3 ubiquitin ligase complex is shown in Figure 5.  
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Figure 4. Schematic overview of the HIV-1 life cycle. HIV-1 binds to CD4 receptor and CCR5 
or CXCR4 co-receptor. This induces fusion of the viral envelope with the cell membrane,  
resulting in the release of the capsid into the cytosol. The genomic RNA is reverse transcribed to 
produce proviral DNA, which is then integrated into host chromosomal DNA. Transcription 
generates viral RNAs that are exported out of the nucleus. Translation of viral RNAs produces 
structural and regulatory HIV-1 proteins. Assembly of viral particles occurs at the plasma 
membrane, after which the immature viral particles bud off. Viral particles mature after the 
release and form new infectious virions. 
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Figure 5. Interactions between Vif, A3G and the E3 ubiquitin ligase complex. Vif binds to 
Elongin C with the conserved SOCS motif, and to Cullin 5 with its zinc-binding motif. 
Association of Vif with E3 ubiquitin ligase allows ubiquitination of A3G. D128 residue in A3G 
is required for its association with Vif. Adapted from Malim and Beniasz 2012.  
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Therefore, in the presence of Vif, A3G is degraded, preventing its incorporation into 
nascent virions (Conticello et al. 2003, Kao et al. 2003, Marin et al. 2003, Sheehy et al. 2003, 
Stopak et al. 2003). In addition, Vif is able to prevent packaging of A3G into virions in a 
degradation-independent manner (Stopak et al. 2003, Mercenne et al. 2003, Opi et al. 2007, Kao 
et al. 2007, Kao et al. 2003). Inactive Vif variants were shown to reduce levels of A3G, 
suggesting that Vif may induce structural changes to prevent incorporation of A3G into virions 
or inhibit its enzymatic activity (Santa-Marta et al. 2005, Britan-Rosich et al. 2011). Overall, Vif 
counteracts the antiviral activity of A3G and therefore allows production of infectious viral 
particles.   
 
1.5 Ribosome inactivating proteins (RIPs) 
1.5.1 General characteristic of RIPs 
Ribosome inactivating proteins (RIPs) are N-glycosidase enzymes ubiquitously expressed 
in different plants, fungi and bacteria (Girbes at al. 2004). These enzymes hydrolyze the N-
glycosidic bond connecting the nitrogenous base to the ribose or deoxyribose in RNA or DNA 
substrates. The enzymatic action of RIPs as glycosidases depurinating ribosomal RNA (rRNA) 
was demonstrated in 1987 (Endo et al. 1987). RIPs depurinate a specific adenine (A4324) found 
within the highly conserved α-sarcin/ricin loop of the 28S rRNA, resuling in the inactivation of 
the ribosome (Endo et al. 1987) (Figure 6A). Depurination of rRNA inhibits the binding of 
elongation factor 2 (EF2), and therefore prevents the GTP-dependent translocation step of 
translation elongation mediated by EF2 (Montanaro et al. 1975, Gessner and Irvin 1980). As a 
consequence of the translation elongation arrest, the ribosome stalls at the point of the 
depurinated base (Gandhi et al. 2008b). Inhibition of protein translation is the cause of the 
observed toxicity of RIPs in cells (Gessner and Irvin 1980, Nilsson and Nygard 1986).   
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Figure 6. Schematic diagram of  RIP N-glycosidase activity and PAP domain organization. 
(A)  RIPs depurinate a specific adenine residue (A4324) located within the highly conserved α-
sarcin/ricin loop of the 28S rRNA, leaving an abasic site. Adapted from Tor and Xie 2009. (B) 
Immature PAP is proteolytically processed by removing 22 amino acids (a.a.) from the N-
terminus and 29 a.a. from the C-terminus to generate 262 a.a. mature PAP. Highly conserved 
SEAARF motif containing  E176 and R179 residues that are directly involved in catalysis is 
located within the active site. Two tyrosine residues (Y72 and Y123) help to hold purine in the active 
site.  
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1.5.2  Classification 
RIPs are classified into 3 major groups, Type I, II and III, based on their physical 
properties (Nielsen and Boston 2011). Type I RIPs contain a single polypeptide chain (A chain) 
of approximately 30-kDa (Nielsen and Boston 2001). Examples of Type 1 RIPs include 
pokeweed antiviral protein (PAP) from Phytolacca, saporin from Saponaria and trichosanthin 
from Tricosanthes (Stirpe 2004, Nielsen and Boston 2001). Type II RIPs consists of an 
enzymatically active A chain linked to lectin binding B chain via a disulfide bond (Stirpe 2004, 
Nielsen and Boston 2001). These heterodimeric Type II RIPs are toxic due to the ability of the 
lectin chain to bind sugars with galactose structure present on glycoproteins and glycolipids 
found on the surface of cell membranes (Nielsen and Boston 2001). This allows their 
endocytosis and translocation into the cytosol (Sandvig and van Deurs 1996).  Ricin and abrin 
are examples of toxins that belong to this group (Stirpe et al. 2004). Type III RIPs are 
synthesized as inactive precursors and require proteolytic processing for activation (Nielsen and 
Boston 2001). Members of this group include JIP60 found in barley and b-32 RIP from maize 
(Stirpe 2004, Peumans et al. 2001).  
1.5.3 Antiviral activity of RIPs 
It is believed that RIPs play a role in defense against pathogens, such as viruses and 
fungi, and can also be involved in stress and senescense responses (Nielsen and Boston 2001). 
The antiviral activity of RIPs against different plant and animal viruses has been characterized, 
although the mechanism is poorly understood (Foà-Tomasi et al. 1982). In plants, RIPs are 
segregated away from ribosomes in cell wall matrix or vacuoles and it is thought that infection of 
a plant with a virus allows the release of the RIP from its sub-cellular compartment into the 
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cytosol and subsequent cell death due to translational inhibition (Nielsen and Boston 2001, Stirpe 
2004). However, the observed inhibition of viral replication in absence of translational inhibition 
suggest that antiviral activity of some RIPs can be dissociated from their ability to depurinate 
rRNA (Tumer et al. 1997, Teltow et al. 1983, Huang et al. 1999, Mansouri et al. 2009). In 
addition, some RIPs were shown to directly depurinate viral RNAs, including human 
immunodeficiency virus type 1 (HIV-1), human T-cell leukemia virus 1 (HTLV-1) and brome 
mosaic virus (BMV) (Rajamohan et al. 1999, Mansouri et al. 2009, Gandhi et al. 2008b). The 
lack of cytotoxicity associated with expression of RIPs in cells contradicts the translational 
inhibition observed when higher concentrations of RIPs were used. Therefore, at low 
concentrations, some RIPs may inhibit viral replication without causing significant cytotoxicity, 
which makes them interesting candidates for biotherapeutic agents against virus infections.   
 
1.6 Pokeweed antiviral protein (PAP) 
1.6.1 General Characteristics 
Pokeweed antiviral protein (PAP) is a Type 1 RIP synthesized by the pokeweed plant, 
Phytolacca americana. In pokeweed, PAP is synthesized as a precursor and undergoes 
proteolytic processing in endoplasmic reticulum (ER). The immature 313 amino acid precursor is 
processed by cleaving 22 amino acid N-terminal signal peptide and 29 amino acid C-terminal 
extension to yield the mature protein (Hur et al. 1995). The mature PAP is targeted into the cell 
wall, thereby segregating it away from ribosomes and preventing its cytotoxic effects (Ready et 
al. 1986). PAP contains a highly conserved SEAARF motif (amino acids 175-180), which 
contains the residues involved in catalysis (Monzingo et al. 1993). Glutamate 176 (E176) is 
located within the active site and its mutation to valine (E176V) renders the protein catalytically 
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inactive (Hur et al. 1995). Arginine 179 (R179) is also universally conserved and involved in 
catalysis (Monzingo et al. 1993). The crystal structure of PAP shows that two tyrosine residues 
(Y72 and Y179) help to coordinate the purine in the active site (Monzingo et al. 1993). 
Mutational studies revealed that an intact C-terminus was required for toxicity and depurination 
of ribosomes in vivo (Tumer et al. 1997). A schematic diagram of PAP structure organization 
and its important residues are illustrated in Figure 6B.   
1.6.2 Antiviral Activity of PAP 
The antiviral activity of PAP was first documented when crude extracts from pokeweed 
leaves were shown to inhibit Tobacco mosaic virus (TMV) infection when they were mixed and 
applied to plant leaves (Duggard and Armstrong 1925). Since then, antiviral activity of PAP 
against many plant and animal viruses, including brome mosaic virus (BMV), herpes simplex 
virus-1 (HSV-1), human T-cell leukemia virus 1 (HTLV-1) and human immunodeficiency virus 
type 1 (HIV-1), was reported (Teltow et al. 1983, Aaron and Irvin 1980, Zarling et al. 1990, 
Rajamohan et al. 1999, Mansouri et al. 2009, Karran and Hudak 2008). PAP inhibited HSV-1 
replication in HeLa and Vero cells at concentrations that were not toxic to the cells (Aaron and 
Irvin 1980). Similarly, inhibition of HTLV-1 replication when PAP was expressed in HEK293T 
cells was not associated with decreased viability (Mansouri et al. 2009). The independence of 
antiviral activity and depurination of ribosomes was further supported when C-terminal mutant 
of PAP was shown to inhibit replication of potato virus X (PVX) while being unable to 
depurinate ribosomes (Tumer et al. 1997). These studies showed that the antiviral activity of 
PAP might be separable from its rRNA depurination ability, suggesting that there is an 
alternative mechanism of limiting virus replication. It is unclear how PAP could preferentially 
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target viral RNAs for depurination, secondary structure or localization of viral RNAs could play 
a role, but further studies are needed to investigate this topic.  
1.6.3 Antiviral activity of PAP against HIV and its application  
 By monitoring adenine release, PAP was shown to depurinate HIV-1 RNAs in 
concentration dependent matter (Rajamohan et al. 1999). Further studies showed that purified 
PAP inhibited HIV-1 production in primary human CD4+ T cells (Zarling et al. 1990). 
Conjugation of PAP to antibodies directed against antigens present of CD4+ T cells forms 
immunotoxins with increased delivery of PAP into plasma membrane. PAP immunoconjugates 
containing antibodies against CD4, CD5 or CD7 antigens present on helper T cells resulted in the 
inhibition of HIV-1 replication at picomolar concentrations of the immunotoxin used and 
increased the anti-HIV activity by 1000-fold (Zarling et al. 1990). Also, the immunoconjugates 
showed a longer plasma half-life compared to free PAP (Zarling et al. 1990). In a separate study, 
an immunoconjugate made up of PAP and anti-CD4 antibody inhibited replication of 22 clinical 
HIV-1 strains at concentrations that did not affect proliferation of CD4+ T cells (Erice et al. 
1993). Administration of an immunotoxin TXU-PAP composed of purified PAP and anti-CD7 
antibody to HIV-1 infected chimpanzees and adult patients decreased HIV-1 RNA levels but no 
sustained therapeutic effect was observed at the concentration tested (Uckun et al. 1999). Some 
complications associated with PAP immunoconjugates included side-effects, such as elevation of 
liver enzymes, short plasma half-life, and generation of antibodies directed against the 
immunotoxin (Uckun et al. 1999). A better understanding of the mechanism of PAP antiviral 
activity could help in a design of therapeutic agents or imunotoxins with more desirable 
characteristics. 
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1.7 Project Goals 
 Previous studies conducted in our lab and elsewhere showed that PAP depurinates HIV-1 
RNAs (Rajamohan et al. 1999, Zhabokristky et al. 2014). Recently, it was shown that PAP 
depurinates Rev RNA, resulting in altered ratio of HIV-1 RNAs (Zhabokritsky et al. 2014). The 
absence of functional Rev protein caused retention of 9-kb and 4-kb RNAs in the nucleus and 
increased their availability for splicing. However, despite the recovery of the splicing ratio when 
Rev was overexpressed in the presence of PAP, the viral protein expression was not rescued 
(Zhabokritsky et al. 2014). Therefore, even if HIV-1 RNAs are exported to the cytosol, they are 
most likely targets for depurination, which results in the inhibition of expression of functional 
viral proteins. In my project, I wanted to investigate if PAP targets Vif mRNA and its impact on 
Vif protein expression and immunity of cells against HIV-1. 
 Since Vif plays a role in infectivity of HIV-1 by counteracting the effect of the host 
restriction factor A3G, I wanted to determine the effect of PAP expression on the infectivity of 
HIV-1 produced in a cell line stably expressing A3G. Previous studies showed that transient 
expression of PAP inhibited HIV-1 production in HEK293T cells by approximately 450-fold 
(Mansouri et al. 2012). However, PAP increased the infectivity of the released viral particles by 
7-fold (Mansouri et al. 2012). This increase in infectivity was attributed to activation of 
extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen activated protein kinase (MAPK) 
pathway and subsequent phosphorylation of p17 matrix protein (Mansouri et al. 2012). This cell 
line does not express A3G, which is expressed endogenously in CD4+ T cells and macrophages, 
the natural targets of HIV-1.  
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 Therefore, my project focused on determining the effect of PAP on Vif expression and its 
impact on the immune response mediated by A3G. I hypothesized that targeting of Vif by 
PAP and the subsequent inhibition of protein expression would lead to elevated A3G levels 
and cause reduced infectivity of HIV-1 particles. To investigate this, I used HEK293 and 
HeLa cells stably expressing A3G to study the effect of PAP on Vif and A3G protein levels. In 
addition, I used the HIV-1 indicator cell line 1G5 to determine the infectivity of HIV-1 virions 
released from PAP expressing cells and the levels of HIV-1 DNA integration.   
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2. MATERIALS AND METHODS 
2.1 Cell culture 
Human embryonic kidney (HEK) 293T cells were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) (Life Technologies) supplemented with 10% fetal bovine serum (FBS) 
(Life Technologies) and penicillin (100 U/ml) and streptomycin (100 μg/ml) at pH 7.4. HEK293-
A3G and HeLa-A3G cells (NIH AIDS Reference and Reagent Program, catalog ue #10203 and 
#9907, respectively) contain stably integrated A3G gene. Cell lines were cultured in DMEM 
supplemented with 10% FBS and G418 disulfate salt (100 μg/ml) (Sigma) at pH 7.4. Cells were 
maintained under G418 selection for passaging, but the antibiotic was removed from media for 
experiments. Cells were grown in polysterene treated plates in a humidified incubator (Thermo 
Electron Corporation HEPA Class 100) at 37°C and 5% CO2. Cells were passaged at 1:5 split 
every second day. Washing of the cells was done with 1X phosphate buffered saline (PBS) (135 
mM NaCl, 5 mM Na2HPO4, 2.5 mM KCl, 2 mM KH2PO4 pH 7.4). Following the wash, 1 ml of 
0.25% Trypsin, 0.1% EDTA was added to allow detachment of the cells.  
H9 lymphocytes (NIH AIDS Reference and Reagent Program, catalogue  #87) were 
cultured in RPMI-1640 (Life Technologies) supplemented with 10% FBS and G418 (50 μg/ml). 
The HIV indicator cell line 1G5 (NIH AIDS Reference and Reagent Program, catalog # 1819) is 
a derivative of Jurkat cell line containing a stably integrated construct consisting of HIV-1 long 
terminal repeat (LTR) upstream of the Luciferase reporter gene. Cells were maintained in RPMI-
1640 supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 μg/ml). Both 
lymphocytic cell lines were maintained at 1 x 10⁵- 1.0 x 10⁶ cells/ml by splitting the cells 1:5 
every second day. Cells were grown in non-treated plates in a humidified incubator at 37°C and 
5% CO2.     
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2.2 Plasmid transfection and cell harvesting 
2.2.1 Plasmid transfection 
For adherent cell lines, cells were plated 18-24 hours prior to transfection to achieve 
optimal 70-80% confluency at the time of transfection. HEK293T cells were transfected using 
calcium phosphate precipitation method. Cells were re-fed with 10 ml of fresh growth medium 3 
hours prior to transfection. Briefly, total plasmid DNA (20-25 μg) was diluted in 405 μl of dH2O 
in 1.5 ml microtube and 45 μl of CaCl2 was added by pipetting. The DNA containing mixture 
was then titrated into 15 ml tubes containing 450 μl of 2X HeBS buffer (350 mM NaCl, 60 mM 
Hepes pH 7.15, 1 mM Na2HPO4) with continuous slow vortexing. Samples were incubated for 
20 minutes at room temperature to allow formation of DNA precipitates, after which they were 
added drop-wise onto plated cells. Transfection efficiency was determined by yellow fluorescent 
protein (YFP) expression using inverted fluorescent microscope (Axiovert) approximately 20 
hours post transfection. Cells were washed with 5 ml of 1X PBS, re-fed with fresh medium and 
incubated for another 24 hours prior to harvesting. 
For HEK293-A3G and HeLa-A3G cells, transfection was performed using 
Lipofectamine2000 reagent (Invitrogen). Cells were seeded in 6-well plates with antibiotic free 
medium to achieve 70-80% confluency at the time of transfection. Plasmid DNA (5-7 μg) was 
diluted in 50 μl of serum-free DMEM. Lipofectamine reagent (8-10 μl) was diluted in 50 μl of 
serum-free DMEM in a separate 1.5 ml microtube and incubated for 5 minutes at room 
temperature. After, diluted DNA was transferred to diluted lipofectamine and mixed gently by 
pipetting. The sample was incubated for 15-20 minutes at room temperature, after which the 
DNA-reagent complex was added drop-wise onto seeded cells.  Cells were washed with 1 ml of 
1X PBS and re-fed with 2 ml of fresh media 20 hours post transfection.  
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H9 lymphocytes were transfected using Lipofectamine2000 reagent. Cells (1.0 x 10⁶) 
were resuspended in 3 ml antibiotic-free media in 6-well non-treated plates. Transfection with 
lipofectamine reagent was performed as described above. Transfection efficiency was estimated 
using YFP expression 20 hours post transfection and cells were harvested 20-24 hours later. 
2.2.2 Harvesting  
Harvesting of transfected adherent cells was performed 44-48 hours post transfection. 
Cells were washed with 1X PBS and resuspended in 1 ml of cold 1X PBS. To pellet the cells, 
samples were centrifuged at 9,000 x g for 5 minutes at 4°C. The supernatants were aspirated and 
the pellets were used for RNA or protein extraction. For harvesting of H9 and 1G5 cells, cells 
were centrifuged at 200 x g for 7 minutes, and washed with 1X PBS. Supernatants were aspirated 
and remaining pellets were used for RNA isolation. 
 
2.3 MTT conversion assay 
HeLa-A3G cells were seeded in 6-well plates to achieve 70-80% confluency at the time 
of transfection. Cells were transfected with pcPAP (0.25 - 1.0 μg), pcPAPx (1.0 μg) or pcDNA3 
(1.0 μg) using Lipofectamine2000 as described above. On the following day, cells were washed 
with 1 ml of 1X PBS and 2 ml of fresh media was added. Cells were washed again and detached 
from the plate 48 hours post-transfection using trypsin solution and resuspended in 1 ml of fresh 
media. Next, 100 μl of resuspended cells were combined with 10 μl of MTT labelling reagent 
(Sigma-Aldrich) in a 96-well plate and incubated for 4 hours at 37°C. Following the incubation, 
100 μl of solubilization buffer (Sigma-Aldrich) was added to each well. The plate was placed 
back into the incubator for additional 2 hours after which the absorbance of the samples was 
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measured at 595 nm wavelength using an ELISA plate reader (Beckman Coulter DTX880 
Multimode Detector). Triplicates for each sample were performed. Values were presented as 
ratios relative to absorbance values obtained from samples transfected with pcDNA3 and 
represent means ± S.E. of three independent experiments.  
 
2.4 RNA isolation 
Cell pellets were lysed with 2 volumes of cytoplasmic lysis buffer (25 mM Hepes, pH 
7.5, 2 mM EGTA, 1 mM DTT, 10% glycerol, 1% NP-40). Samples were vortexed, placed on ice 
for 10 minutes, and centrifuged at 14,000 x g for 10 minutes at 4°C to pellet cell debris. 
Supernatants were transferred to new 1.5 ml microtubes and 0.5 ml of Trizol (Molecular 
Research Center) and 100 μl of chloroform were added. Samples were vortexed, incubated at 
room temperature for 5 minutes and centrifuged at 16,000 x g for 10 minutes at 4˚C. Top, RNA-
containing aqueous layer was transferred to new 1.5 ml microtubes and 0.5 ml of isopropanol 
and 10 μg of glycogen was added. RNA was precipitated at -20°C for 18 hours, followed by 
centrifugation at 16,000 x g for 30 minutes at 4°C. Pellets were air-dried and resuspended in 150 
μl of dH20. Next, 150 μl of phenol:chloroform:isoamyl alcohol (PCI) (25:24:1) was added, 
samples were vortexed and centrifuged at 16,000 x g for 5 minutes at room temperature. The top 
layer was extracted and 2.5 volumes of 100% ethanol and 1/10 volume of 3M NaOAc were 
added. RNA was precipitated at -20°C for 18 hours, followed by centrifugation at 16,000 x g for 
30 minutes at 4°C. The supernatant was discarded and the pellet was washed with 70% ethanol 
by centrifuging the samples at 16,000 x g for 15 minutes at 4°C. Pellets were air-dried and 
resuspended in 15-30 µl of dH2O. RNA was quantified using spectrophotometer (Beckman 
DU530 Life Sciences) at OD260 nm.   
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2.5 RNA Immunoprecipitation 
To determine whether PAP associated with Vif RNA in vivo, immunoprecipitation of 
PAP-bound RNAs was performed. Cells were transfected with constructs encoding codon 
optimized Vif (pc-hVif) and PAP and the media was aspirated 48 hours post transfection, 
followed by washing of the cells with 5 ml of 1X PBS. After the wash, 7 ml of cold 1X PBS was 
added to the cells and RNA was crosslinked to proteins by irradiating the cells at 260 nm at 150 
mJ/cm
2
 for 10 minutes. After the generation of RNA-protein crosslinks, the cells were harvested 
by resuspending them in the 1X PBS and centrifuged at 4,000 x g for 5 minutes. The supernatant 
was aspirated and the resulting pellets were lysed with 2 volumes of cytoplasmic lysis buffer (25 
mM Hepes, pH 7.5, 2 mM EGTA, 1 mM DTT, 10% glycerol, 1% NP-40). Samples were 
vortexed and placed on ice for 10 minutes, and centrifuged at 14,000 x g for 10 minutes at 4°C to 
pellet cell debris. Cell lysates were transferred to new 1.5 ml microtubes.  
Goat anti-rabbit IgG magnetic beads (New England Biolabs) were resuspended in the 
supplied buffer by vortexing and rotating for 1.5 hours at 4˚C. After, 15 µl of resuspended beads 
was aliquoted to 1.5 microtubes and washed 3 times with 1X ribonucleoprotein (RNP) buffer 
(150 mM NaCl, 20 mM Hepes pH 7.4, 0.5% Triton X, 0.1% Tween 20, 8 units of RNase OUT) 
by adding 1 ml of the buffer, exposing the beads to a magnet (Dynal) and drawing them to the 
side to allow removal of the supernatant. Washed beads were resuspended in 200 µl of 1X PBS 
and incubated with 5-10 µg of rabbit polyclonal PAP antibody by rotating the 1.5 ml microtubes 
for 2 hours at 4˚C. Polyclonal PAP antibody-coated beads were then washed 3 times with 1X 
RNP buffer and cell lysates were added after the removal of the supernatant. Cell lysates were 
incubated with the coated beads by rotating the samples for 30 minutes at 4˚C. Samples were 
then washed 4 times with 1X RNP buffer and finally resuspended in 500 µl of 1X RNP buffer.  
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Proteins were digested by incubating the samples with 1% SDS and 3 units of proteinase 
K (BioShop) for 30 minutes at 30˚C. Following the incubation, proteins were removed by adding 
500 µl of phenol:chloroform:isoamyl alcohol (PCI) (25:24:1). Samples were mixed by vortexing, 
centrifuged at 16,000 x g for 5 minutes at room temperature and the top layer was extracted. 
RNA was precipitated with 900 µl of 100% ethanol and 10 µg of glycogen at -20˚C overnight 
followed by centrifugation at 16,000 x g for 30 minutes at 4˚C. Supernatant was discarded and 
the pellet was washed with 500 µl of 70% ethanol by centrifuging the sample at 16,000 x g for 
15 minutes at 4˚C. After air-drying the pellet for 5 minutes, the RNA was resuspended in 10 µl 
of dH2O. The resuspended RNA was then used in RT-qPCR analysis to quantify levels of Vif 
RNA. 
 
2.6 Reverse transcription (RT) 
For the reverse transcription reaction, 10 µl of resuspended RNA obtained from RNA 
immunoprecipitation or 1-3 µg of cytosolic RNA harvested from transfected cells was used in a 
total volume of 10 µl. Appropriate reverse primer (0.2 µg) was added and samples were 
denatured at 95˚C for 3 minutes. Sequences of all primers used are listed in Table 1. Following 
the heating, samples were placed on ice for 1 minute and 2 µl of 5X first-strand buffer (375 mM 
KCl, 250 mM Tris-HCl pH 8.3, 15 mM MgCl2, 5 mM DTT) was added. Primer was allowed to 
anneal by incubating the sample for 10 minutes at room temperature. After the incubation, 2 µl 
of first-strand buffer, 2 µl of 0.1 M DTT, 2 µl of 10 mM dNTPs, 2 µl of dH2O, 40 units of RNase 
inhibitor (New England Biolabs) and 20 units of Moloney-murine leukemia virus reverse 
transcriptase (M-MuLV RT) (New England Biolabs) were added to each reaction. Samples were   
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Table 1. List of primers used in this study. The names of primers along with 
their sequences and melting temperatures are listed below. 
 
Primer name Sequence (5' - 3') 
TM 
(°C) 
 hVif 431 F CTCTACAGTACTTGGCACTAGCAGC 64.3 
 hVif 679 R CTAGTGTCCATTCATTGTATG 58.4 
 HXB2 5200 F CCTCATCCAAGAATAAGTTCAG 59.3 
 HXB2 5350 R CTGCTAGTTCAGGGTCTACT 55.2 
 hVif 173 F GATTAGCAGCGAGGTGCACATTCC 71.4 
 hVif 383 R ATACGTCCTAATATGGTATTTC 59.9 
 HXB2 5460 R GGTGTGAATATCAAGCAGGACATAAC 65.3 
 5S rRNA 24 F GGGCCGGATCCCATCAGAACTCC 77.8 
 5S rRNA 96 R CCCAGGAGGTCACCCA 69.8 
 28S rRNA dep R AGTCATAATCCCACAGATGGT 53.4 
 28S rRNA R TTCACTCGCCGTTACTGAGG 57.2 
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incubated for 90 minutes at 48˚C, followed by heat-inactivation of the enzyme at 70˚C for 10 
minutes. Heat-inactivated samples were then used in quantitave-PCR (qPCR) analysis. 
 
2.7 Quantitative PCR (q-PCR) 
For qPCR analysis, 4-10 μl of RT reaction product was used. For each reaction, cDNA 
was combined with 1.85 μg of gene-specific forward and reverse primer, 33 μl of SYBR 
Advantage qPCR Premix (Clontech) and the reaction volume was brought up to 66 μl with 
dH2O. The sample was then mixed by pipetting and aliquoted into 0.2 ml single tubes (ABgene) 
to make 20 μl triplicates. For each sample, cDNA encoding 5S rRNA was used as an internal 
control and was prepared as described above in a separate reaction. Rotor-Gene Q was used to 
carry out the qPCR reaction, which was set up as follows: initial hold at 50°C for 20 seconds and 
denaturation at 95°C for 10 minutes followed by 40 cycles alternating between denaturation at 
95° for 15 seconds and annealing of the primer and extension at 58°C for 60 seconds. The 
reaction was ended with a final melt at 95°C for 5 minutes. Data were then analyzed with Rotor-
Gene Q Series Software and then Ct values were obtained. For each sample, 3 technical 
replicates and minimum of 3 biological replicates were examined. Comparative quantification 
algorithm ΔCt was used for quantification of relative Vif RNA levels from the RNA-
immunoprecipitation experiment. The calibrator was chosen to be the sample transfected with 
pc-hVif and the fold difference between Vif RNA in test samples and calibrator was computed as 
2^ΔCt.  
For quantification of Vif RNA levels in HEK293T cells and H9 lymphocytes transfected 
with the HIV proviral clone pMenv(-) and pc-hVif, respectively, ΔΔCt method was used. In this 
32 
 
quantification, 5S rRNA was used as the normalizer gene. Both test sample and calibrator 
samples were adjusted in relation to a normalizer gene Ct from the same two samples. For 
HEK293T cells, samples transfected with the proviral clone pMenv(-) served as a calibrator 
sample, whereas for H9 cells, sample transfected with pc-hVif served as a calibrator sample. 
Mock sample contained RNA harvested from untransfected cells, whereas no RNA sample 
contained primers only and served as a control for primer amplification.     
 
2.8 Primer extension 
2.8.1 Preparation of radiolabelled reverse primers 
For primer extension analysis, Vif-specific reverse primers were end-labelled with γ33P-
dATP. In a 1.5 ml microtube, 0.2 μg of reverse primer, 50 μCi of γ33P-dATP (Perkin Elmer), 1 μl 
of 10X T4 polynucleotide kinase  buffer (700 mM Tris-HCl pH 7.6, 100 mM MgCl2, 50 mM 
DTT), 20 units of T4 polynucleotide kinase (New England Biolabs) were combined and the 
reaction volume was brought up to 10 μl with dH2O. Sample was incubated for 1 hour at 37°C 
after which the reaction was stopped by the addition of 1 μl of 0.5M EDTA and diluted with 40 
μl of dH2O. The unincorporated nucleotides were removed by adding the sample to a G-50 
centrifuge column (Thermo Scientific) containing 700 μl of G-50 sephadex solution (GE 
Healthcare) and centrifuging it at 2,700 x g for 2 minutes at room temperature. The flowthrough 
containing the radiolabelled primer was collected and the sample was stored in -20°C or used in 
primer extension analysis. 
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2.8.2 Primer extension 
Samples containing cytoplasmic RNA (20-40 μg) harvested from HEK293T cells 
transfected with pcPAP and pMenv(-) or pc-hVif were combined with  5 x 10
5
 CPM of Vif-
specific radiolabelled reverse primer. The reaction volume was brought up to 11 μl with dH20 
and the sample was heated for 5 minutes at 95°C followed by cooling for 2 minutes on ice. The 
primer was allowed to anneal to the template by incubating the sample for 10 minutes at 58°C 
followed by incubation for 3-5 minutes at room temperature. Samples was centrifuged to collect 
all the liquid and 4 μl of 5X first-strand buffer (375 mM KCl, 250 mM Tris-HCl pH 8.3, 15 mM 
MgCl2, 5 mM DTT), 2 μl 0.1M DTT, 1 μl of 10 mM dNTPs and 40 units of RNase inhibitor 
(New England Biolabs) were added. Samples were heated for 2 minutes at 48°C after which 20 
units of M-MuLV reverse transriptase enzyme (New England Biolabs) were added to the sample 
and incubated for additional 50 minutes at 48°C. The primer extension reaction was stopped by 
heating the sample at 70°C for 10 minutes and the addition of 10 μl of RNA loading dye (95% 
formamide, 20 mM EDTA, 0.25% bromophenol blue, 0.25% xylene cyanol). Prior to loading of 
the samples on the large sequencing gel (7M urea, 6% acrylamide), the samples were heated for 
4 minutes at 90°C  and chilled on ice for 2 minutes. From each sample, 6 μl was loaded onto a 
gel and the RT products were separated at 30 Watts for 2.5-3.5 hours. After electrophoresis, the 
gel was placed against a thin filter paper and air dried using a gel dryer (Thermo Savant) under a 
vacuum for 2 hours at 80°C. Next, the dried gel was placed against phosphor imaging screen 
(BIO-RAD) overnight and scanned in a GE Healthcare Typhoon Trio+ Variable Mode Imager. 
The resulting image was analyzed with Quantity One 1D-analysis software.   
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2.9 Sequencing ladder 
Manual dideoxynucleotide sequencing was performed to generate ladders that were used 
to identify the sequence of nucleotides in cDNA products generated in the primer extension 
analysis. Plasmid template, pMenv(-) or pc-hVif, was denatured by combining 8-16 μg of 
plasmid DNA with 2 μl of 2M NaOH, 2 μl of 2 mM EDTA and the total volume was brought up 
to 22 μl with dH2O. Samples were incubated for 6 minutes at room temperature, after which 2 μl 
of 2M NH4OAc pH 4.6 and 75 μl of 95% ethanol were added. Plasmid DNA was precipitated 
overnight at -20°C followed by centrifugation at 16,000 x g for 20 minutes at 4°C. Next, the 
supernatant was discarded and the pellet was air-dried and resuspended in 7 μl of dH2O. Each 
sample was combined with 2 μl of reaction buffer (250 mM NaCl, 200 mM Tris-HCl pH 7.5, 
100 mM MgCl2) and 0.2 μg of the appropriate reverse primer. The primer was annealed by 
incubating the sample for 2 minutes at 65°C followed by gradual cooling to 35°C over 25-30 
minutes period after which the sample was chilled on ice for 5 minutes. Meanwhile, 4 
termination tubes were prepared each containing 2.5 μl of one of the dideoxynucleotides. For 
each sequencing reaction, 1 μl of 0.1 M DTT, 0.4 μl of labeling mix (0.75 μM dGTP, 7.5 μM 
dCTP, 7.5 μM dTTP), 6.25 μCi of 35S dATP (Perkin Elmer), 3.25 units of Sequenase DNA 
polymerase (USB Corp.), 1.75 μl of dilution buffer (10 mM Tris-HCl pH 7.5, 5 mM DTT, 0.1 M 
EDTA), 0.42 μl of dimethyl sulfoxide (DMSO), and 1.6 μl of dH2O were combined and added to 
the denatured DNA-containing sample. The reaction was incubated for 5 minutes at room 
temperature after which 3.5 μl of the sample was aliquoted into each of the 4 termination tubes. 
Samples were incubated for 5 minutes at 37°C, after which 4 μl of stop solution (95% 
formamide, 20 mM EDTA, 0.25% bromophenol blue, 0.25% xylene cyanol) was added. Samples 
were heated at 75°C for 2 minutes and 4 μl of each termination reaction was loaded onto a large 
sequencing gel alongside primer extension reaction products.    
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2.10 Protein Isolation 
Cell pellets were lysed with 2 volumes of cytoplasmic lysis buffer. Samples were 
vortexed and placed on ice for 10 minutes, and centrifuged at 14,000 x g for 10 minutes at 4°C to 
pellet cell debris. Supernatants were transferred to new 1.5 ml microtubes and protein 
concentrations were determined by Bradford assay (OD595 nm). Next, 2X Laemmli buffer (125 
mM Tris-HCl pH 6.8, 20% glycerol, 10% β-mercaptoethanol, 4%SDS, 0.25% bromophenol 
blue) was added and samples were heated at 95˚C for 5 minutes. Denatured protein samples were 
stored in -20˚C or used in western blot analysis. 
 
2.11 Western blotting 
Denatured protein samples were resolved by sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE). Samples were loaded onto a 12% acrylamide gel and the 
proteins were separated at 200V for 40 minutes in 1X running buffer (192 mM glycine, 25mM 
Tris-HCl pH 8.3, 0.1% SDS). Semi-dry transfer (BIO-RAD) was used to transfer the resolved 
proteins from the gel onto a nitrocellulose membrane (GE Healthcare). The blot was rinsed in 
western transfer buffer (160 mM glycine, 25 mM Tris-HCl pH 8.3, 20% methanol, 0.02% SDS) 
prior to the transfer. The gel was placed on top of a nitrocellulose membrane and four pieces of 
thick chromatography paper (Fisher Scientific) were placed under and over to form a sandwich. 
Proteins were transferred at 0.12 Amp for each membrane for 40 minutes. Following the transfer, 
the membrane was blocked with 10 ml of 5% milk in PBS-T (1X PBS with 0.1% Tween 20) for 
2 hours by gentle rocking at room temperature. Next, membrane was incubated with the 
appropriate amount of primary antibody (Table 2) in 5 ml of 5% milk in PBS-T by gentle  
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Table 2. List of antibodies. Antibodies used in immunoprecipitation and western blotting 
experiments are listed below.  
 
Antibody  
Supplier and catalogue 
# 
Final 
concentration Experiment 
 
Rabbit PAP polyclonal  
gift of N. Tumer Rutgers 
University 1:5,000 
RNA-
immunoprecipitation 
 Mouse HA monoclonal Sigma Aldrich H9658 1:20,000 western blot 
 Mouse HIV-1 Vif  
monoclonal NIH #6459 1:2,500 western blot 
 Mouse HIV-1 Vif  
monoclonal Santa Cruz sc-69731 1:500 western blot 
 Rabbit APOBEC3G 
polyclonal NIH #10082 1:10,000 western nlot 
 
Mouse Actin monoclonal 
Novus Biologicals 
NB100-74340 1:5,000 western blot 
 Rabbit VSV-G polyclonal GenScript A00199-40 1:5,000 western blot 
 Anti-Mouse secondary Sigma Aldrich A9044 1:5,000 western blot 
 Anti-Rabbit secondary Sigma Aldrich A4914 1:5,000 western blot 
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rocking at 4˚C overnight. The membrane was then washed with 1X PBS-T buffer by gentle 
rocking for 10 minutes. A total of 3 washes was performed after which the membrane was 
incubated with the appropriate secondary antibody conjugated to a horseradish peroxidase 
enzyme (Table 2) in 5 ml of 5% milk in 1X PBS-T. The membrane was then washed as 
described above and incubated with 1.5 ml of enhanced chemiluminescence (ECL) reagent 
(Perkin Elmer) for 2 minutes at room temperature. The membrane was then exposed to a clear 
blue x-ray film (Thermo Scientific) for 5-15 minutes and developed in the dark. The membrane 
was stripped with 10 ml of 8M guanidine hydrochloride (G-HCl) by gentle rocking at room 
temperature to allow re-probing of the blot with different antibodies. The membrane was washed 
3 times with 1X PBS-T with gentle rocking and blocked prior to the addition of different primary 
antibody. Blocking, incubation with antibodies and washes were performed as described.  
 
2.12 Plasmid transformation 
Transformation of plasmid DNA was performed in competent E.Coli DH5α cells. 
Thawed competent cells (100 µl) were mixed with plasmid DNA (0.3-1 µg) by gentle pipetting 
in 1.5 ml microtube and incubated on ice for 30 minutes. Samples were then heat-shocked for 1 
minute at 42˚C and placed on ice for 2 minutes. Next, 300 µL of Luria-Bertani (LB) media was 
added to each sample and the cells were incubated in the media with shaking at 150 rpm for 1 
hour at 37˚C. Following the incubation, the cells were pelleted at 5,000 x g for 10 minutes at 
room temperature. Supernatant was removed to leave about 100 µl of LB media above the pellet, 
which was used to resuspend the cells. Resuspended cells were then plated onto LB plates coated 
with 20 µl of ampicillin (100 µg/µl). Plates were placed into incubator at 37˚C overnight after 
which colony formation was examined. Colonies were selected and the harvested plasmid DNA 
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was used for sequencing. Positive colonies were used in large scale plasmid isolation to obtain 
high yield of purified plasmid DNA. 
 
2.13 Large scale plasmid isolation 
LB cultures (4 ml) containing 0.4 µg of ampicillin were inoculated with selected colonies 
and  incubated with shaking at 250 rpm for 18 hours at 37˚C. Next, the overnight 4 ml cultures 
were transferred to 400 ml LB cultures containing 40 µg of ampicillin and incubated by shaking 
at 250 rpm at 37˚C for additional 18 hours. The cultures were then transferred to 250 ml Oak 
Ridge polycarbonate centrifuge bottles and the cells were pelleted by centrifuging the samples at 
4,000 x g for 10 minutes at 4˚C.  The supernatant was discarded and the pellets were washed by 
resuspending them in 25 ml of 1X STE (100 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA 
pH 8.0) followed by centrifugation at 4,000 x g for 10 minutes at 4˚C. The supernatant was 
discarded and the remaining pellet was resuspended in 10 ml of cold solution 1 (50 mM glucose, 
25 mM Tris HCl pH 8.0, 10 mM EDTA).  Cells were lysed with the addition of 20 ml of solution 
2 (0.2 M NaOH, 1% SDS), vortexed and placed on ice for 4 minutes. Next, 10 ml of solution 3 
(3M KOAc, 12% glacial acetic acid) was added and the sample was vortexed and incubated on 
ice for 10 minutes. Following the incubation, samples were centrifuged at 4,000 x g for 10 
minutes at 4˚C and the plasmid DNA-containing supernatants were filtered through 8 layers of 
cheesecloth. Approximately 20 ml of cold isopropanol was added and the DNA was precipitated 
at -20˚C for 1 hour. Next, the samples were centrifuged at 4,000 x g for 20 minutes at room 
temperature and the pellets were air dried for 3 minutes. Pellets were then resuspended in 5 ml of 
1X TE buffer (10 mM Tris HCl pH 8.0, 1 mM EDTA) and transferred to 15 ml tubes containing 
7 g of cesium chloride (CsCl). Samples were vortexed to dissolve CsCl, additional TE buffer was 
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added to bring the volume of the solution to 9 ml and 0.5 ml of 10 µg/µl ethidium bromide was 
added. Samples were mixed throughoutly by vortexing and centrifuged at 4,000 x g for 7 
minutes at room temperature. The DNA-containing supernatant was transferred into bell-top 
ultracentrifuge tube (Beckman) using glass pipette and centrifuged at 155,000 x g for 22 hours at 
22˚C. The band containing the supercoiled DNA was extracted with hypodermic needle and the 
obtained sample was diluted with 1X TE buffer to a final volume of 5 ml. Ethidium bromide was 
removed from the plasmid DNA-containing sample with 5 washes with isoamyl alcohol. During 
each wash, 5 ml of isoamyl alcohol was added to the sample, vortexed, the layers were allowed 
to separate and the top layer was removed. After the last wash, the volume of the sample was 
brought to 5 ml with 1X TE and 10 ml of 100% ethanol was added. Samples were precipitated 
overnight at -20˚C and centrifuged at 4,000 x g for 20 minutes at 4˚C. The supernatant was 
discarded and the remaining pellet was washed twice with 70% ethanol by centrifuging the 
sample at 4,000 x g for 10 minutes at 4˚C. After discarding the supernatant, the pellet was air-
dried and resuspended in 100-500 µl of 1X TE and the DNA was quantified using 
spectrophotometer at OD 260 nm.  
 
2.14 Virus particle isolation 
Viral particles were isolated from media collected from cells transfected with the HIV 
proviral clone pMenv(-) 44 hours post-transfection. Pseudotyping of viral particles was 
performed using glycoprotein G of vesicular stomatitis virus by co-transfecting pCMV-VSV-G 
(1-3 μg) with the pMenv(-) proviral clone. Media containing viral particles was transferred to 1.5 
ml microtubes and centrifuged at 9,000 x g for 5 minutes to pellet cell debris. The supernatant 
was transferred to new 1.5 ml microtube and centrifuged at 16,000 x g for 90 minutes at 4˚C to 
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pellet viral particles. Supernatant was aspirated and the pellet was resuspended in fresh media. 
For ELISA analysis, 1X lysis buffer (10% Triton X-100 in Milli-Q H2O) and sample diluent 
media (1% BSA, 0.2% Tween 20 in RPMI-1640) were added to the samples. 
 
2.15 Enzyme-linked immunosorbent assay (ELISA) 
To quantify viral particles released from HeLa-A3G cells, HIV-1 p24 CA ELISA 
(National Cancer Institute, Frederick National Laboratory, MA) was used. Viral particles were 
harvested as described above and 1/10 volume of lysing solution (10% Triton X-100 in Milli-Q 
H2O) was added. Samples were vortexed well and incubated for 1 hour at 37°C. Meanwhile, 2-
fold serial dilutions of standard (p24
CA
 40,170 pg/ml) was prepared using sample diluent. ELISA 
plate was washed 4 times with 1X Wash Concentrate (2 mM imidazole, 160 mM NaCl, 0.02% 
Tween 20, 0.5 mM EDTA) (KPL) and blotted on a clean paper towel to dry between the washes. 
After, 100 μl of standards and samples were aliquoted in duplicates into wells. In addition, 2 
wells were left empty and 2 wells were filled with sample diluents which served as a blank and a 
background control, respectively. The plate was then sealed and incubated for 2 hours at 37°C. 
After incubation, the plate was washed as described above and 100 μl of rabbit anti-HIV-1 (MN) 
p24 antibody diluted (1:300) in primary antibody diluent (10% FBS, 2% normal mouse serum 
(NMS) in RPMI-1640) was added to each well except the blank wells. Plate was sealed and 
incubated for 1 hour at 37°C. After incubation with primary antibody, washes were performed as 
described above and goat anti-rabbit IgG secondary antibody conjugated to horse radish 
peroxidase was diluted (1:200) in secondary antibody diluent (5% normal goat serum (NGS), 2% 
NMS, 0.01% Tween 20 in RPMI-1640) and 100 μl of diluted antibody was added to each well 
except the blank wells. The plate was sealed and incubated for 1 hour at 37°C. After incubation 
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with secondary antibody, the plate was washed as described above and 100 μl of 3,3’,5,5’-
tetramethylbenzidine (TMB) peroxidase substrate  (KPL) was added to each well and incubated 
for 30 minutes at room temperature. The reaction was then stopped with the addition of 100 μl of 
1M HCl and the yellow-coloured product was quantified using an ELISA plate reader (Beckman 
Coulter DTX880 Multimode Detector) at 450 nm absorbance using the Beckman Coulter 
Multimode Analysis Software. The data were then analyzed with ElisaAnalysis report (ElisaKit) 
using 4 parameter logistic ELISA curve fitting.    
 
2.16 Infectivity assay 
Single-cycle infectivity assays were performed using pseudotyped HIV-1 virions. 
Pseudotyped virions harvested from PAP, PAPx or pcDNA3 expressing HeLa-A3G cells were 
quantified by HIV-1 p24 CA ELISA and equal amounts (5 ng) were used to infect 1G5 cells. 
Infections of 1G5 cells (2.5 x 10⁵ cells) were performed in 24-well plate in a presence of 8 μg of 
polybrene in a final volume of 1.5 ml of DMEM supplemented with 10% FBS. After 20 hours, 
cells were centrifuged at 200 x g for 7 minutes at 4°C and the supernatant was aspirated. The 
pelleted cells were washed with 1 ml of 1X PBS by centrifuging at 200 x g for 7 minutes at 4°C. 
The supernatant was aspirated and the cells were resuspended in 2 ml of fresh media and 
incubated for additional 24 hours at 37°C. Cells were harvested by centrifugation at 200 x g for 7 
minutes at 4°C, the supernatant was aspirated and the cells were lysed with the appropriate lysis 
buffer.  
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2.17 Luciferase assay 
For the luciferase assay, 50 μl of the 1X Luciferase Cell Culture Lysis Reagent 
(Promega) was added to pelleted cells and the samples were vortexed for 15 seconds. After, 
samples were centrifuged at 12,000 x g for 15 seconds at room temperature and the supernatant 
was transferred to new 1.5 ml microtubes. The lysates were stored in -20°C or used to quantify 
luciferase expression with a single-tube luminometer with injectors (EG&G Berthold Lumat LB 
9507 Ultra Sensitive Tube Luminometer). Cell lysates (20 μl) were aliquoted into 5 ml tubes 
(Sarstedt) and 100 μl of the Luciferase Assay reagent (Promega) was dispensed into the 
luminometer tubes. The luminometer was programmed to perform a 2-second measurement 
delay followed by a 10-second measurement read for luciferase activity.     
 
2.18 PCR for detection of HIV-1 DNA in infected 1G5 cells 
Pseudotyped virions harvested from PAP, PAPx or pcDNA3 expressing HeLa-A3G cells 
were quantified by HIV-1 p24 CA ELISA and equal amounts (10 ng) were used to infect 1G5 
cells (2.5 x 10⁵). Cells were washed and resuspended in fresh media 4 hours post-infection. DNA 
was harvested by adding 100 μl of nuclear lysis buffer (150 mM NaCl, 25 mM Tris-HCl pH 7.6, 
1% NP-40, 1% sodium deoxycholate, 0.1% SDS) to cell pellet 24 hours post-infection. PCI 
extraction was performed, after which DNA was precipitated in 2.5 volumes of 100% ethanol 
and 1/10 volume of 3M NaOAc. RNA was precipitated at -20°C for 18 hours, followed by 
centrifugation at 16,000 x g for 30 minutes at 4°C. The supernatant was discarded and the pellet 
was washed with 70% ethanol by centrifuging the samples at 16,000 x g for 15 min at 4°C. HIV-
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1 DNA was amplified using Vif-specific primers (Table 1). DNA fragment encoding 5S rRNA 
was amplified using 5S rRNA-specific primers (Table 1), which served as a loading control.  
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3. RESULTS 
3.1 PAP depurinates rRNA without causing cell toxicity 
PAP is known to depurinate a specific adenine residue (A4324) within the conserved α-
sarcin/ricin loop in the eukaryotic 28S rRNA. To confirm the expression and activity of PAP in 
HeLa-A3G cells, pc-PAP construct encoding 3X-FLAG-tagged PAP was transiently transfected 
and primer extension was carried out to determine if 28S rRNA was depurinated. A construct 
encoding a catalytically inactive mutant of PAP, pcPAPx, was used as a control. PAPx has a 
point mutation in the active site (E176V) which abolishes its ability to depurinate RNA (Hur et 
al. 1995). Expression of wild-type PAP resulted in depurination of 28S rRNA as shown by a 
band indicating termination of primer extension at the predicted adenine residue (Figure 7A). By 
comparing the intensity of the band at A4324 relative to total 28S rRNA, it was estimated that 
PAP depurinated approximately 15% of the rRNA. As expected, PAPx did not depurinate 28S 
rRNA (Figure 7A).  
In addition, to confirm that the expression of PAP at the concentration used in the 
experiments (0.5 - 1 μg) was not toxic to HeLa-A3G cells, an MTT conversion assay was 
performed. Cells transfected with pcPAP showed no decline in cell viability compared to cells 
transfected with pcPAPx or pcDNA3, an empty vector (Figure 7B). Therefore, PAP was 
efficiently expressed in HeLa-A3G cells and did not cause cytotoxicity at the concentration used. 
 
3.2 PAP associates with Vif RNA in vivo 
To determine whether PAP associates with Vif RNA in vivo, immunoprecipitation of 
PAP-bound RNA followed by RT-qPCR with Vif-specific primers was performed. HEK293T 
cells were transfected with pcPAP and pc-hVif, encoding codon-optimized Vif for efficient  
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Figure 7. PAP depurinates rRNA without cell toxicity. (A) HeLa-A3G cells were transfected 
with pMenv(-) (5 μg) and pcPAP or pcPAPx (1 μg). Cells were harvested 44 hours post-
transfection and primer extension was performed on cytosolic RNA (3 μg) to determine the level 
of rRNA depurination relative to the total amount of 28S rRNA. Dideoxynucleotide sequencing 
of 28S rDNA with the same primer (28S rRNA dep R) used for primer extension confirmed the 
location of rRNA depurination by PAP. Another primer (28S rRNA R) was used as a control for 
total 28S rRNA in each sample. Mock represents untransfected cells. (B) Viability of cells 
expressing PAP or PAPx was tested by an MTT conversion assay 48 hours post-transfection. 
Values are presented as ratios relative to samples transfected with pcDNA3 for 3 independent 
experiments.  
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Figure 8. PAP associates with Vif RNA in vivo. HEK293T cells were transfected with pc-hVif 
(3 μg) and pcPAP (2.5 μg). Cells were crosslinked by UV and lysed 44 hours post transfection. 
Immunoprecipitation was performed on cell lysates incubated with magnetic beads coated with 
PAP polyclonal antibody. RNA was extracted from beads and used in RT-qPCR with Vif-
specific primers (hVif 431F and hVif 579R). Mock sample contained untransfected cells, while 
no RNA sample contained primers only. Values are the means   ± S.E. of 3 independent 
experiments. 
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expression. This cell line was chosen due to its high transfection efficiency and the codon-
optimized vector, pc-hVif, was used to achieve high expression of Vif RNA. 
Immunoprecipitation was performed with magnetic beads coated with PAP polyclonal antibody. 
RNA was harvested from the beads and RT-qPCR analysis was performed using Vif-specific 
primers (Table 1). Samples co-transfected with pcPAP and pc-hVif showed approximately 8-fold 
higher Vif RNA levels compared to samples transfected with pcPAP or pc-hVif alone (Figure 8). 
Mock sample contained untransfected cells, and no RNA sample served as a control for primer 
amplification. Overall, in vivo RNA pulldown assay showed association of PAP with Vif mRNA. 
 
3.3  PAP decreases Vif mRNA and protein levels. 
3.3.1 PAP decreases Vif mRNA levels, which is partially rescued by the overexpression of Rev. 
In order to determine the effect of PAP on Vif mRNA expressed from the HIV-1 proviral 
clone pMenv(-), RT-qPCR was performed on cytosolic RNA using Vif-specific primers (Table 
1). The plasmid encoding pMenv(-) is derived from the HXB2 HIV-1 strain, but is unable to 
express env gene due to mutation in its start codon (Sadaie et al. 1992). HEK293T cells were 
transfected with pcPAP, pcRev encoding the regulatory HIV-1 protein Rev, and pMenv(-). RT-
qPCR using Vif-specific primers allowed me to determine if the expression of PAP alters the 
levels of the 4 kb mRNA from which Vif is expressed, as well as the full-length 9 kb RNA, since 
Vif ORF is present in both transcripts. Depurination in a region of Vif ORF that is being reverse 
transcribed would cause stalling of the enzyme. Therefore, only non-depurinated mRNA 
containing Vif ORF would be reverse transcribed and amplified through RT-qPCR. PAP  
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 Figure 9. PAP decreases the levels of Vif mRNA and protein. (A) HEK293T cells were 
transfected with pMenv(-) (5 μg), pcPAP (2.5 μg) and pcRev (2.5 μg). Cells were harvested 44 
hours post transfection  and cytosolic RNA (1-3 μg) was extracted for RT-qPCR analysis with 
Vif-specific primers (HXB2 5200F and HXB2 5350R). The levels of Vif mRNA were 
standarized relative to 5S rRNA. Mock sample represents untransfected cells, and no RNA 
serves as a negative control for primer amplification. (B) HEK293T cells were transfected with 
pMenv(-) (5 μg), pcPAP (2.5 μg) and pcRev (2.5 μg). Cytoplasmic proteins were harvested 40 
hours post transfection and analyzed by western blotting. Protein samples (200 μg) were 
separated on a 12% SDS-PAGE, transferred to nitrocellulose and probed with Vif-specific 
monoclonal antibody (1:500) and β-actin-specific monoclonal antibody (1:10,000), which was 
used as a loading control. Mock sample served as a negative control since it contained 
untransfected cells. Blot is a representative of 3 independent experiments. (C) H9 lymphocytes 
were transfected with pc-hVif (3 μg) and pcPAP (1 μg). Cells were harvested 44 hours post-
tranfection and cytosolic RNA (1-3 μg) was extracted for RT-qPCR analysis using Vif-specific 
primers (hVif 173F and hVif 383R). The levels of Vif mRNA were standarized relative to 5S 
rRNA. Values are the means ± S.E. of 3 independent experiments. 
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decreased the levels of cytosolic Vif mRNA 3-fold compared to cells transfected with pMenv(-) 
(Figure 9A). Therefore, in the presence of PAP, levels of cytoplasmic intact Vif mRNA were 
reduced. The export of 4-kb and 9-kb mRNAs from the nucleus is dependent on Rev, which is 
encoded by the 2-kb class of mRNAs. Reduced levels of Vif mRNA in the presence of PAP 
could be due to PAP targeting the 2-kb transcripts from which Rev is expressed and subsequent 
inhibition of nuclear export of the 4-kb transcripts. Therefore, the effect of Rev overexpression 
when pcPAP and pMenv(-) were co-transfected was tested. Overexpression of pcRev in the 
presence of PAP resulted in 2-fold increase in Vif mRNA levels, but did not fully recover Vif 
mRNA levels (Figure 9A).  
3.3.2 PAP inhibits Vif protein expression, which is not rescued by the overexpression of Rev. 
In order to analyze Vif protein levels in samples transfected with pMenv(-), pcPAP, and 
pcRev, western blotting was performed using cytosolic proteins harvested 40 hours post 
transfection. A sample transfected with pMenv(-) alone showed a band that agreed with the 
molecular weight of Vif (Figure 9B). This band was not detected in samples co-transfected with 
pcPAP and pcRev, (Figure 9B), suggesting that overexpression of Rev in the presence of PAP 
did not rescue Vif protein expression.  
3.33 PAP reduces Vif RNA levels in H9 lymphocytes  
In addition, I wanted to determine the effect of PAP on Vif mRNA levels in a 
lymphocytic cell line, which would be more biologically relevant since HIV-1 naturally infects 
CD4+
 
T cells and macrophages. The lymphocytic cell line used was H9, which expresses A3G 
endogenously. Relative Vif mRNA levels expressed from the pc-hVif clone were determined by 
RT-qPCR using hVif-specific primers (Table 1). The codon-optimized clone was used in H9 
51 
 
cells instead of the proviral clone to achieve high Vif RNA expression despite low transfection 
efficiency of the lymphocytic cell line. PAP expression caused approximately 3-fold reduction in 
Vif mRNA levels (Figure 9C). Therefore, the results obtained in H9 lymphocytes supported the 
trends observed with HEK293T cells, indicating that PAP reduces intact Vif mRNA levels, 
present either as an ectopically expressed RNA or from the context of the HIV-1 genome.   
 
3.4 PAP depurinates Vif ORF when expressed from pc-hVif or pMenv(-).  
Since PAP is an N-glycosidase and reduction in intact Vif mRNA levels was observed in 
the presence of PAP, I wanted to determine whether PAP depurinates Vif mRNA. Primer 
extension was performed to investigate whether the downregulation of Vif mRNA levels could 
be due to depurination of Vif ORF. HEK293T cells were transfected with pcPAP and pc-hVif or 
pMenv(-). Transfection of pc-hVif tested whether PAP targeted Vif mRNA in the absence of 
other HIV-1 proteins, whereas transfection of pMenv(-) allowed determination of potential 
depurination sites within Vif ORF in the context of the native 4-kb mRNA. Samples were co-
transfected with pcPAP or pcDNA3, an empty vector used as a control. Total RNA was extracted 
40 hours post transfection and used in primer extension with a radiolabelled reverse primer that 
annealed to Vif ORF (362-383 for hVif and 5435-5460 for HXB2 Vif). The cDNA products 
were separated by electrophoresis and visualized by autoradiography. The presence of cDNA of 
shorter length compared to full length extension in samples co-transfected with pcPAP would 
suggest a possible depurination site as reverse transcriptase pauses at apurinic sites, leading to 
termination of primer extension. After performing primer extension of RNA isolated from 
samples co-transfected with pc-hVif and pcPAP, I detected a band corresponding to a unique  
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Figure 10. PAP depurinates Vif RNA. HEK293T cells were transfected with pcPAP (2.5 μg) 
and either (A) pc-hVif (3μg) or (B) pMenv(-) (5 μg). Cytoplasmic RNA was extracted 44 hours 
post transfection for primer extension analysis (20 or 40 μg) with radiolabelled primer 
complementary to a region of Vif ORF (362-383 for hVif and 5435-5460 for HXB2 Vif). cDNA 
products were separated on 7M urea, 6% acrylamide gel and visualized by autoradiography. 
Sequencing ladders were generated by manual dideoxynucleotide sequencing of either pc-hVif 
or pMenv(-) using the same reverse primers. Gels are represenative of 5 independent 
experiments. (C) Schematic diagram of the locations of depurination found in Vif RNA 
expressed from either pc-hVif or the proviral clone pMenv(-). The numbering is based on the 
HIV-1 HXB2 strain (accession number K03314.5). 
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termination of primer extension. Comparison of this band to a sequencing ladder generated by 
manual dideoxynucleotide sequencing of pc-hVif showed that reverse transcriptase stalled 
immediately 3’ to (before) a guanine (G) residue (G5252 relative to HXB2 genome or G212 
relative to hVif) found within Vif ORF (Figure 10A). This depurination band was observed 
consistently in several independent experiments.  
Primer extension performed on samples co-transfected with pMenv(-) and pcPAP 
revealed depurination sites at specific adenine (A5222) and guanine (G5309) residues found in 
Vif ORF present in the HIV-1 HXB2 strain genome (Figure 10B). The 2 depurination bands 
were observed consistently in several independent experiments and differed from the 
depurination site detected in hVif mRNA. Overall, primer extension analyses revealed that Vif 
RNA is a template for depurination by PAP when expressed from either pc-hVif or pMenv(-) 
constructs.  
 
3.5 Both HIV-1 Vif and hVif downregulate levels of A3G.  
Vif is known to inhibit the activity of the cellular cytidine deaminase A3G by targeting it 
for destruction (Yu et al. 2003, Sheehy et al. 2003, Stopak et al. 200). In order to confirm that 
Vif expressed from both pMenv(-) and pc-hVif is able to decrease the levels of A3G in 
HEK293T cells, cells were co-transfected with pMenv(-) or pc-hVif and HA-tagged A3G. 
Samples transfected with pMenv(-) or pc-hVif showed a single band of approximately 23 kDa, 
which agreed with the molecular weight of Vif protein (Figure 11). Transfection of HA-A3G 
alone resulted in a band of approximately 46 kDa, corresponding with the known molecular 
weight of A3G enzyme (Figure 11). Co-transfection of either pMenv(-) or pc-hVif with HA-  
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Figure 11. Vif decreases A3G levels in HEK293T cells. Cells were co-transfected with 
pMenv(-) (5 µg) or pc-hVif (2.5 µg) and pcHA-A3G (2.5 µg) and total cytosolic proteins were 
harvested 44 hours post-transfection. Protein samples (100 µg) were separared on a 12% SDS-
PAGE and analyzed by western blotting using Vif-specific (1:2,500), HA-specific (1:20,000) and 
β-actin-specific (1:5,000) monoclonal antibodies. Β-actin served as a loading control. The dashed 
line indicates removal of lanes from the gel. Blot is representative of 3 independent experiments. 
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tagged A3G A3G showed a band corresponding to Vif protein of the same intensity, but much 
thinner band for HA-A3G, suggesting that Vif is able to downregulate A3G in these cells (Figure 
11). Therefore, expression of Vif from pMenv(-) or pc-hVif generated a functional Vif protein. 
 
3.6 PAP, but not PAPx, decreases Vif protein levels when expressed from pc-hVif or 
pMenv(-) constructs. 
Next, I wanted to further investigate the effect of PAP on Vif protein expression. 
pMenv(-) or pc-hVif were transfected into HEK293T cells along with pcPAP or pcPAPx. 
Comparing levels of Vif expressed from pMenv(-) and pc-hVif in the presence of pcPAP 
allowed me to determine whether downregulation of Vif by PAP was dependent on other 
proteins encoded by HIV-1 or whether PAP could decrease Vif protein levels when transfected 
alone. Protein samples isolated from cells transfected with pMenv(-) or pc-hVif showed a single 
band of approximately 23 kDa, corresponding to Vif protein (Figure 12). Co-transfection of 
pMenv(-) or pc-hVif with pcPAP resulted in a decrease of Vif protein to undetectable levels. In 
contrast, co-transfection of pcPAPx, a mutant lacking catalytic activity, did not change the levels 
of Vif protein in either the pMenv(-) or pc-hVif sample (Figure 12). The mock sample served as 
a negative control, since it contained untransfected cells.  
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Figure 12. PAP decreases levels of Vif protein when expressed from pc-hVif or pMenv(-). 
HEK293T cells were co-transfected with pc-hVif (2.5 µg) or pMenv(-) (5 µg) and pcPAP or 
pcPAPx (2.5 µg). Mock sample contained untransfected cells. Cytosolic proteins were harvested 
40 hours post-transfection and used for western blotting analysis (100 µg). Samples were 
separated on 12% SDS-PAGE gel, transferred to nitrocellulose, and the blot was probed with 
Vif-specific monoclonal antibody (1:2,500) and β-actin-specific monoclonal antibody 
(1:10,000), which was used as a loading control. Blot is representative of 3 independent 
experiments. 
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3.7 Decreased levels of Vif in the presence of PAP result in elevated levels of A3G in HeLa-
A3G cells.  
Knowing that PAP downregulates Vif, I wanted to see if this leads to elevated A3G levels 
since Vif induces degradation of A3G. To explore the effect of PAP on A3G, I used HEK293 
and HeLa cells stably expressing A3G. These cells lines were chosen since the A3G gene is 
stably integrated and therefore variation in the expression levels is minimized compared to 
differences introduced during transient expression. Transfection of pc-hVif resulted in decreased 
A3G levels in both cells lines, which agrees with Vif’s role in degradation of A3G (Figure 13A 
and C). Co-transfection of pcPAP resulted in decreased Vif levels and the amount of A3G 
returned to original levels in both cell lines (Figure 13A and C). Therefore, PAP downregulation 
of Vif leads to increased levels of A3G, an enzyme involved in host anti-viral response against 
HIV-1. Transfection of pcPAP or pcPAPx alone did not alter levels of A3G (Figure 13A and C). 
A3G levels were also decreased in both cell lines when pMenv(-) was transfected and rescued by 
the addition of pcPAP (Figure 13B and D).  
 
3.8 PAP decreases HIV-1 viral particle release. 
To examine the effect of PAP on viral particle release, HeLa-A3G cells were transfected 
with pMenv(-) and a gradient of pcPAP (0.25-1 μg). HeLa-A3G cells were used instead of 
HEK293-A3G cells due to their better transfection efficiency. Viral particles were collected from 
the media 44 hours post transfection and used in p24 ELISA analysis to quantify the amounts of 
HIV-1 virions released from PAP, PAPx or pcDNA3-expressing cells. PAP decreased HIV-1 
viral particle release by approximately 100-fold at the highest PAP concentration tested 
compared to PAPx or pcDNA3 controls (Figure 14). Inhibition of HIV-1 particle release by PAP  
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Figure 13. Decreased levels of Vif in the presence of PAP correlate with increased levels of 
A3G. (A) HEK293 cells stably expressing HA-A3G were transfected with pc-hVif (3 µg) and 
pcPAP or pcPAPx (1 µg). Cytosolic proteins were harvested 44 hours post transfection and used 
for western blot analysis (100 µg). Protein samples were separated on 12% SDS-PAGE, 
transferred to nitrocellulose, and the blot was probed with Vif-specific (1:500), HA-specific 
(1:20,000) and β-actin-specific (1:10,000) monoclonal antibodies. Β-actin was used as a loading 
control. (B) HEK293 cells stably expressing HA-A3G were transfected with pMenv(-) (5µg) and 
pcPAP or pcPAPx (1 µg). (C) HeLa-A3G cells were transfected with pc-hVif (3 µg) and pcPAP 
or pcPAPx (1 µg). (D) HeLa-A3G cells were transfected with pMenv(-) (5µg) and pcPAP or 
pcPAPx (1 µg). Blot was probed A3G-specific antibody (1:10,000) and the same Vif and β-
actin-specific antibodies as listed above. Each blot is representative of 5 independent 
experiments. 
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Figure 14. PAP decreases HIV-1particle release from HeLa-A3G cells. HeLa-A3G cells were 
transfected with pMenv(-) (3 µg) and pcPAP (0.25-1.0 µg), pcPAPx (1.0 µg) or pcDNA3 (1.0 
µg). Viral particles were collected from the media 44 hours post transfection and HIV-1 Gag p24 
levels were quantified by ELISA. Values are means ± S.E. of 3 independent experiments.  
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occurred in a concentration-dependent manner (Figure 14). Performing ELISA on HIV-1 
particles released from PAP, PAPx or pcDNA3 expressing cells also allowed quantifying and 
equalizing the amount of virus used in subsequent experiments. 
 
3.9 PAP reduces infectivity of released HIV-1 virions and decreases HIV-1 proviral DNA 
levels in target cells. 
Since PAP downregulates Vif resulting in rescue of A3G levels, I wanted to examine the 
effect of elevated levels of A3G in the presence of PAP on virus infectivity. Viral particles were 
pseudotyped using glycoprotein G of vesicular stomatitis virus (VSV-G) and used to infect 1G5 
cells. HIV-1 LTR activation was assessed by measuring luciferase activity in cell lysates. 
Activation of LTR requires efficient expression of HIV-1 regulatory protein Tat and therefore 
successful infection and expression of HIV-1 RNAs and proteins are required for luciferase 
expression. VSV-G pseudotyped virions were produced in HeLa-A3G cells by co-transfection of 
pMenv(-), p-CMV-VSV-G and pcPAP,  pcPAPx or pcDNA3. Virions from PAP-expressing cells 
were approximately 11-fold less infectious, as indicated by decreased luciferase activity, 
compared to virions from pcPAPx or pcDNA3-expressing cells. Therefore, PAP reduces HIV-1 
particle release and the released viral particles are less infectious. 
Packaging of A3G into HIV particles in the absence of Vif is associated with decreased 
HIV-1 reverse transcript accumulation and DNA hypermutation (Harris et al. 2003, Mangeat et 
al. 2003, Yu et al. 2004, Zhang et al. 2003). Since HIV-1 particles released in the presence of 
PAP are less infectious, I wanted to examine the effect of PAP in producer HeLa-A3G cells on 
the levels of integrated HIV-1 DNA in target cells. Pseudotyped HIV-1 virions released from 
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Figure 15. PAP decreases infectivity of HIV-1 virions and lowers the amount of integrated 
HIV-1 DNA in target cells. (A) HeLa-A3G cells were co-transfected with pMenv(-) (3 μg), p-
CMV-VSV-G (1.0 µg) and pcPAP, pcPAPx or pcDNA3 (0.5 μg). Viral particles were collected 
from the media 44 hours post-transfection and HIV-1 Gag p24 levels were quantified by ELISA. 
Equal amounts of pseudotyped virus (5 ng) were used to infect 1G5 cells (1.0 x 10
5 
cells). 
Following 40 hours of incubation, cells were collected, lysed and luciferase activity was 
measured to to determine relative virus infectivity. Renilla lucirefase units (RLU) obtained from 
cells co-transfected with pcPAP, pcPAPx or pcDNA3 were subtracted from RLU values from 
mock sample which contained untransfected cells. The relative luciferase activity was obtained 
as a ratio of RLU values from pcPAPx or pcDNA3 expressing cells to pcPAP expressing cells. 
Values are means ± S.E. of 3 independent experiments. (B) 1G5 cells were infected with viral 
particles released from pcPAP, pcPAPx or pcDNA3 expressing cells as described above and the 
presence of integrated HIV-1 DNA was determined by PCR analysis 24 hours post-infection 
using Vif specific primers (HXB2 5200F and HXB2 5350R). 
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HeLa-A3G cells transfected with pcPAP, pcPAPx or pcDNA3 were quantified by ELISA and 10 
μg was used to infect 1G5 cells. DNA was harvested from cells 24 hours post infection and used 
in PCR analysis with Vif-specific primers. A band corresponding to the expected product size of 
approximately 150 nucleotides was seen in samples infected with virions produced from pcPAPx 
and pcDNA3-expressing cells (Figure 15B). There was no product visible in cells infected with 
virions released from PAP-expressing cells (Figure 15B). Therefore, the expression of PAP in 
producer HeLa-A3G cells lowered the amount of integrated HIV-1DNA in infected Jurkat cells. 
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4. DISCUSSION 
4.1 PAP as an antiviral agent 
Previous studies have shown that pokeweed antiviral protein (PAP) has a broad anti-viral 
activity against different plant and animal viruses. Because of its ability to inhibit replication of 
some animal viruses, including human immunodeficiency virus type 1 (HIV-1), human T cell 
leukemia virus 1 (HTLV-1) and herpes simplex virus (HSV), PAP has been of a great interest to 
many researchers and its application as a biotherapeutic agent has been pursued (Zarling et al. 
1990, Rajamohan et al. 1999, Mansouri et al. 2009, Teltow et al. 1983, Aaron and Irvin 1980). 
Initially, the inhibition of virus replication was attributed to rRNA depurination, resulting in the 
reduction of host cell translation (Foà-Tomasi et al. 1982). Ribosome depurination induces 
ribotoxic stress response, which can result in apoptosis (Narayanan et al. 2005). However, it was 
shown previously that ribosome depurination following expression of a RIP in yeast was not 
sufficient to induce cell death (Li et al. 2007). The ability of PAP to target and depurinate HIV-1 
RNAs and inhibit virus production without causing cytotoxicity (Zarling 1990, Rajamohan et al. 
1999) suggested an alternative mechanism of virus restriction. In addition, a C-terminal mutant 
of PAP retained its anti-viral activity, but was unable to depurinate ribosomes, indicating that 
rRNA depurination might be separable from PAP effect on viruses (Tumer et al. 1997).  
Exploiting the anti-HIV activity of PAP, immunoconjugates consisting of the antiviral 
protein and antibodies targeted to antigens present on helper T cells were tested for their ability 
to inhibit HIV-1 replication and decrease viral burden (Zarling et al. 1990, Erice et al. 1993, 
Uckun et al. 1999). PAP-antibody conjugates were found to severely restrict HIV-1 production at 
picomolar concentrations while causing minimal toxicity (Zarling et al. 1990). Administration of 
PAP-containing immunoconjugates to chimpanzees and HIV-1 infected human patients showed 
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promising results, including decreased HIV-1 RNA levels; however, no sustained therapeutic 
effect was achieved (Uckun et al.1999).  
 The studies conducted in our lab showed that PAP inhibits HIV-1 protein expression and 
decreases viral particle release in HEK293T cells by approximately 450-fold (Mansouri et al. 
2012). However, HIV-1 particles released from PAP-expressing cells were 7-fold more 
infectious (Mansouri et al. 2012). The host deaminase enzyme APOBEC3G (A3G) 
endogenously expressed in CD4+ T cells and macrophages severely restricts replication of HIV-
1 mutants lacking functional viral infectivity factor (vif) gene and decreases infectivity of the 
virions (Strebel et al. 1987, Harris et al. 2003, Mangeat et al. 2003, Zhang et al. 2003, Lecossier 
et al. 2003). A3G is not expressed in adherent cell lines such as HEK293T cells and therefore the 
impact of PAP on immune defense provided by A3G was not considered in the study performed 
by Mansouri et al. 2012. In addition, since PAP was shown to depurinate different HIV-1 RNAs 
(Zhabokritsky et al. 2014), the goal of my study was to determine if PAP depurinates Vif mRNA 
and its subsequent impact on the cellular innate immunity mediated by A3G. To do this, I 
investigated the effect of transient expression of PAP on Vif and A3G protein levels in cell lines 
stably expressing A3G, in addition to assessing virion production and infectivity.  
 
4.2 Depurination of rRNA by PAP is not toxic to cells. 
The well documented substrate of PAP is the rRNA, and in vitro studies have shown that 
depurination of rRNA inhibits the binding of elongation factor-2 (EF-2) to ribosomes, causing 
toxicity to cells through general inhibition of cellular translation (Gessner and Irvin 1980, 
Nilsson and Nygard 1986). Toxicity has been posited as the mechanism of antiviral activity, as 
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cell death would limit virus production (Foà-Tomasi et al. 1982). Expression of PAP in HeLa-
A3G cells resulted in depurination of 28S rRNA at the predicted adenine (A4324) (Figure 7A). 
Moreover, the level of rRNA depurination was approximately 15%, which agrees with previous 
studies (Chan Tung et al. 2008, Mansouri et al. 2012). Studies conducted in HEK293T cells 
showed similar level of ribosome depurination and demonstrated that this degree of depurination 
is not sufficient to inhibit the rate of cellular translation (Mansouri et al. 2009, Chan Tung et al. 
2008). In addition, PAP did not affect the viability of HeLa-A3G cells as shown by the MTT 
assay performed on the cells transfected with a gradient of PAP (Figure 7B). Therefore, these 
findings suggested that depurination of viral RNAs, rather than cellular translation machinery is 
responsible for the antiviral effect of PAP and the degree of ribosome depurination associated 
with the transient expression of PAP was not sufficient to induce cell death.  
 
4.3 PAP binds and decreases the levels of Vif mRNA and protein 
Zhabokritsky et al. previously showed that PAP depurinates regulator of expression of 
virion proteins (rev) mRNA, resulting in decreased levels of 9-kb and 4-kb HIV-1 RNAs in the 
cytosol (Zhabokritsky et al. 2014). Since overexpression of Rev in the presence of PAP 
recovered the splicing ratio of HIV-1 RNAs but did not rescue HIV-1 protein expression, it was 
possible that PAP targeted and depurinated 9-kb and 4-kb RNAs once they were exported out of 
the nucleus (Zhabokritsky et al. 2014). In my study, I wanted to determine if the 4-kb RNA from 
which Vif is expressed is targeted by PAP, resulting in decreased Vif protein levels.  
Immunoprecipitation of PAP-bound RNAs showed that PAP interacts with Vif mRNA 
(Figure 8). In addition, Figure 9A shows that PAP decreased the levels of cytosolic Vif mRNA 
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expressed from the proviral clone pMenv(-) 3-fold relative to cells transfected with pMenv(-) 
alone. Overexpression of Rev increased the levels of Vif RNA by 2-fold, but did not fully 
recover it (Figure 9A).  Therefore, even in the presence of Rev, when 4-kb mRNA from which 
Vif is expressed is exported out of the nucleus, Vif mRNA levels are decreased in the presence 
of PAP. In comparison, Vif protein levels were decreased to undetectable amounts when PAP 
was present and overexpression of Rev did not change the amount of Vif protein (Figure 9B). 
The lack of an increase in Vif protein amount when Rev was overexpressed as seen in Figure 9B 
contradicts the 2-fold increase in the Vif RNA levels. Therefore, although cytosolic levels of Vif 
RNAs are recovered by the overexpression of Rev, these RNAs are not translated, suggesting 
that PAP damages them. PAP may be depurinating 2 kb transcripts first, resulting in a lack of 
Rev protein required for the export of 9 kb and 4 kb transcripts. Therefore, in the absence of Rev, 
decreased levels of Vif mRNA can be due to nuclear retention. However, since overexpression of 
Rev did not lead to full recovery of Vif mRNA in the presence of PAP, PAP may also be 
targeting Vif mRNA directly and depurinating it, resulting in decreased amount of Vif mRNA 
detected by RT-qPCR. 
The 3- fold decrease in Vif RNA levels in the presence of PAP was also shown in H9 
lymphocytic cell line which expresses A3G endogenously (Figure 9C). Therefore, H9 
lymphocytes, more physiologically relevant cells for HIV-1 infection, supported the trend 
observed in HEK293T cells, indicating that PAP reduces Vif mRNA levels, present either as an 
ectopically expressed RNA or from the context of the HIV-1 genome.   
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4.4 PAP directly depurinates Vif mRNA 
Although the ability of PAP to target and depurinate different HIV-1 RNAs has been 
shown (Zarling et al. 1990, Zhabokritsky et al. 2014), depurination of Vif mRNA has not been 
demonstrated.  Figure 10A and B show that depurination was detected in Vif RNA when 
expressed from pc-hVif (G5252) clone or the HIV proviral clone (A5222 and C5309). 
Depurination of RNA substrate leaves an intact ribose-phosphate backbone, but generates a 
nucleotide missing a purine base. Previous study showed that translating ribosome stalls at 
apurinic sites, resulting in the inhibition of the synthesis of the full-length protein (Gandhi et al. 
2008b). In yeast, stalling of the ribosome at the depurinated site within brome mosaic virus 
(BMV) RNA3 was correlated with increased degradation of the RNA through the No-go decay 
(NGD) pathway (Gandhi et al. 2008b). However, the consequence of RNA depurination in 
mammals remains unclear and it is not known whether stalling of the ribosome at apurinic sites 
is associated with accelerated degradation in a similar way as observed in yeast.  
The depurination sites in Vif RNA expressed from the pMenv(-) proviral clone differed 
from the depurination site detected in hVif mRNA, perhaps due to differences in mRNA 
sequences and folding, as the primary sequence in hVif clone was optimized by 26% in this 
region (Nguyen et al. 2004) and the transcripts vary in size considerably. Vif ORF exists in a 
context of 4-kb transcript when expressed from the proviral clone compared to only the sequence 
representing the Vif ORF present in the pc-hVif clone. Therefore, differential folding of the 
RNAs may alter the structure and therefore identity of the nucleotide base targeted by PAP, 
implying that structure of the RNA may be important for PAP specificity. Currently, unpublished 
data from our laboratory suggest that high degree of secondary structure in viral RNAs might be 
favoured by PAP (Jobst and Hudak). In contrast, analysis of the reported depurinated sites within 
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BMV, HTLV-1 and HIV-1 RNAs showed no sequence similarity, implying that sequence does 
not determine the specificity of PAP for viral RNAs (Jobst and Hudak).     
 
4.5 Decreased Vif protein levels in the presence of PAP are correlated with increased A3G 
levels.  
Vif targets A3G for destruction, thereby counteracting its anti-viral activity (Yu et al. 
2003, Marin et al. 2003, Mehle et al. 2004, Sheehy et al. 2003, Stopak et al. 2003). PAP inhibited 
Vif expression when either construct was used, pc-hVif or pMenv(-), indicating that PAP can 
target Vif in the absence of the other HIV- proteins (Figure 12). In addition, since PAPx did not 
alter levels of Vif, downregulation by PAP is dependent on its catalytic activity (Figure 12). The 
loss of Vif protein expression in the presence of PAP can be explained by the depurination 
detected in Vif RNA expressed from the pc-hVif or pMenv(-) constructs.  
To determine the effect of the inhibition of Vif expression by PAP on A3G levels, HeLa 
and HEK293 cells containing stably integrated A3G gene were used. Data from Figure 13 
showed that PAP inhibited Vif expression in these cell lines and rescued cytosolic A3G levels. 
The rescue of A3G expression detected by western blot was similar to recovery of A3G levels 
seen in other studies when HIVΔvif mutants were used (Bishop et al. 2008, Sheehy et al. 2003). 
The degree of inhibition of Vif activity directly affects the ability of A3G to restrict viral 
propagation. Given that Vif was not detected in PAP-expressing cells and A3G levels were 
recovered to those of untransfected cells, PAP might be efficient at restricting viral propagation. 
In addition, the ability of PAP to decrease expression of other HIV-1 proteins is beneficial as it 
affects multiple steps in the viral life cycle rather than specifically inhibiting Vif action. 
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In vivo studies showed an inverse correlation between A3G expression levels and HIV-
viremia (Jin et al. 2005). Long-term non-progressors (LTNPs) had the highest A3G mRNA 
levels, followed by HIV-uninfected subjects and progressors (Jin et al. 2005). These studies 
imply that inhibition of Vif function might significantly reduce HIV-1 virus loads in vivo and 
restrict viral propagation. Therefore, Vif-A3G interaction could be used as a novel target for anti-
retroviral therapy. Different strategies have been attempted to either disrupt Vif-A3G interaction 
or increase A3G levels, as potential anti-HIV therapies. For example, libraries of small 
molecules have been screened to identify compounds that inhibit Vif-A3G binding, its 
deaminase activity, extend A3G stability or disrupt the assembly of the E3 ligase complex with 
A3G and Vif (Cen et al. 2010, Nathans et al. 2008, Matsui et al. 2014, Ali et al. 2012, Zuo et al. 
2012). Small molecules that enhanced Vif degradation showed increased A3G encapsidation and 
hypermutation of HIV-1 DNA (Nathans et al. 2008). Over-expression of A3G has been 
accomplished by treatment of cells with interferon (Chen et al. 2010). Delivery of vectors 
containing the A3G gene fused to viral protein Vpr or non-pathogenic variant of Nef showed 
resistance of the fusion protein to Vif-mediated degradation (Ao et al. 2011, Ao et al. 2008, 
Green et al. 2009). These strategies have diminished virus production; however, the natural 
balance between Vif and A3G levels needs to be considered when evaluating potential therapies.  
There is growing evidence that HIV-1 uses A3G to promote quasispecies evolution of the 
virus (Simon et al. 2005, Sadler et al. 2010, Smith 2011, Wood et al. 2009). Perhaps incomplete 
inhibition of Vif would maintain A3G at low levels that would serve to create new, potentially 
more fit, variants of the viral genome. There is evidence that cytidine deamination provides a 
source for viral diversification and facilitate HIV-1 escape from immunological and 
pharmaceutical inhibition (Simon et al. 2005, Wood at al. 2009). Many drug-resistance mutations 
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were shown to reside in A3G hotspots, suggesting that mutations introduced by A3G give rise to 
HIV-1 variants resistant to common anti-HIV drugs (Berkhout and deRonde 2004). In addition, 
mutations in cytotoxic T cell (CTL) epitopes were found in A3G hotspots (Wood et al. 2009). 
CTLs play an important role in adaptive immunity in elimination of virally infected cells and 
mutations in CTL epitopes were shown affect activation of these cells (Borrow et al. 1997). 
Therefore, this alternate view that A3G can promote virus fitness must be carefully considered 
when designing drugs that inhibit Vif function and provides a challenge when designing 
therapeutic approaches aimed at disturbing the Vif-A3G interaction.  
 
4.6 PAP decreases infectivity of HIV-1 virions and reduces levels of integrated HIV-1 
proviral DNA in infected cells. 
Previous studies showed that PAP decreases HIV-1 particle release from HEK293T cells 
by 450-fold (Mansouri et al. 2012). However, HIV-1 virions released from PAP-expressing cells 
were 7-fold more infectious, which was attributed to the activation of ERK1/2 MAPK pathway 
and subsequent phosphorylation of p17 matrix protein (Mansouri et al. 2012). The increase in 
infectivity of HIV-1 virions in the presence of PAP was compensated by the significant reduction 
in virus particle release, resulting in overall decrease in virus production upon de novo infection 
of cells over 21-day period (Mansouri et al. 2012). Activation of ERK1/2 MAPK signalling 
pathway is thought to be triggered by depurination of 28S rRNA; PAP and other RIPs have been 
shown to induce a ribotoxic stress response following the damage to the ribosome (Iordanov et 
al. 1997). Although apoptosis is often the end-result of ribotoxic stress response (Iordanov et al. 
1997), the activation of c-Jun NH₂-terminal kinase (JNK) when PAP was transiently expressed in 
HEK293T cells did not result in cell death (Chan Tung et al. 2008). Overall, studies conducted in 
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HEK293T cells showed that PAP increases infectivity of HIV-1 virions by activating MAPK 
pathways (Chan Tung et al. 2008, Mansouri et al. 2012). However, these studies were conducted 
in a cell line that does not express A3G. Since A3G significantly reduces infectivity of HIV-1 
virions in the absence of functional Vif protein, I investigated the effect of PAP expression in 
HeLa-A3G cells on HIV-1 particle release and infectivity. 
Transient expression of PAP in HeLa-A3G cells reduced HIV-1 particle release in 
concentration dependent manner (Figure 14). Approximately 100-fold reduction was observed at 
the highest concentration of PAP tested (Figure 14). This concentration of PAP was shown to not 
cause change in cell viability (Figure 7B). The difference in the reduction of HIV-1 particle 
release observed in HeLa-A3G cells and reported in HEK293T cells (Mansouri et al. 2012) could 
be due to differences between cells lines and transient tranfection settings, including variable 
amount of DNA vectors used and transfection efficiency. 
To determine the effect of PAP on infectivity of HIV-1 virions released from HeLa-A3G 
cells, HIV-1 particles pseudotyped with VSV-G were used to infect 1G5 cells, a derivative of 
Jurkat cell line stably expressing a luciferase reporter gene downstream of HIV-1 long terminal 
repeat (LTR). Activation of the LTR requires efficient expression of HIV-1 regulatory protein 
Tat which is the primary regulator of HIV-1 transcription (Berkhout et al. 1989). Therefore, 
successful infection and expression of HIV-1 RNAs and proteins are required for Luciferase 
expression. Virions from PAP-expressing cells were approximately 11-fold less infectious, as 
indicated by decreased luciferase activity, compared to virions from PAPx or pcDNA3 cells 
(Figure 15A). Other studies showed 10-1000 fold decrease in infectivity of HIV-1Δvif virions 
(Strebel 1987, Mangeat et al. 2003, Mariani et al. 2003, Kao et al. 2003, Sheehy et al. 2003, 
Miyagi et al. 2007). This wide range of reported reduction in viral infectivity in the absence of 
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Vif could be due to use of different cell lines expressing variable levels of A3G, use of transient 
transfection to express A3G exogenously, different proviral clones and experimental procedures.  
Overall, PAP expression lowered production of infectious HIV-1 particles; 100-fold 
reduction in release of viral particles and 10-fold decrease in infectivity of virions were shown. It 
is likely that PAP also activates MAPK pathways in HeLa cells, although this has not been 
demonstrated and requires further investigation. If PAP induces phosporylation of p17 matrix 
protein in HeLa cells in a similar way as observed in HEK293T cells, then the activity of A3G 
outweights the effect of PAP on MAPK pathway activation and its subsequent impact on 
infectivity. However, activation of the MAPK pathway and phosphorylation of p17 matrix 
protein upon transfection of PAP into HeLa cells not expressing A3G should be first evaluated 
before drawing conclusions about the contradictory results observed between the two cell lines.  
The 100-fold decline in virus particle release from PAP-expressing cells did not provide 
enough material to confirm the presence of A3G in released HIV-1 particles. Therefore, to test 
the activity of A3G, I wanted to determine the levels of integrated HIV-1 DNA in target 1G5 
cells since A3G reduces reverse transcript accumulation and integration of proviral DNA (von 
Schwedler et al. 1993, Goncalves et al. 1996, Mariani et al. 2003, Mangeat et al. 2003). 
Expression of PAP in producer HeLa-A3G cells significantly reduced the amount of integrated 
proviral HIV-1 DNA in target 1G5 cells (Figure 15B). Other studies showed 5-50 fold reduction 
in integration efficiency of HIV-1Δvif viruses (Mangeat et al. 2003, Mariani et al. 2003, Luo et 
al. 2007). The absence of HIV-1 proviral DNA in 1G5 cells did not allow me to investigate 
hypermutation status. It would be of interest to determine the reduction in integrated HIV-1 
DNA more quantitatively by performing qPCR and using primers than span different regions of 
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HIV-1 DNA to confirm the results and analyze sequences to determine if hypermutation occurs 
when a gradient of PAP is transfected into producer cells.  
  
4.7 Anti-HIV-1 activity of PAP and its application 
In my study, I showed that PAP reduced HIV-1 particle production and the released 
virions were less infectious. This effect on infectivity was attributed to inhibition of Vif 
expression by PAP and its subsequent impact on A3G. Therefore, I propose a model in which 
increased A3G levels in the presence of PAP reduce the release of infectious viral particles and 
inhibit further viral propagation (Figure 16). Previous studies performed in our lab showed that 
PAP depurinates other HIV-1 RNAs, including Rev RNA, thereby inhibiting different steps of 
the viral life cycle (Zhabokritsky et al. 2014). Inhibition of Rev activity resulted in nuclear 
retention of 9-kb and 4-kb RNAs (Zhabokritsky et al. 2014). The lack of recovery of HIV-1 
protein expression when Rev was overexpressed suggested that when exported out of the 
nucleus, 9-kb and 4-kb HIV-1 RNAs can be templates for depurination. Because of its ability to 
inhibit the expression of multiple viral proteins simultaneously and decrease the release of 
infectious virions, PAP could act as a potential therapeutic agent against HIV-1.  
Current treatments involve administration of combination of drugs, each targeting 
different steps of the HIV-1 life cycle to minimize the chance of drug resistance arising due to 
the highly mutagenic nature of HIV-1. Some of the drugs currently used include nucleoside and 
non-nucleoside analogs that inhibit reverse transcriptase and protease (Barre-Sinoussi et al. 2013, 
Siliciano et al. 2013). Per round of replication, HIV-1 RT introduces on average 5-10 mutations 
in HIV-1 genome (Preston et al. 1988). Analyses of the misincorporated bases showed  
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Figure 16. Model for inhibition of Vif by PAP and its impact on A3G-mediated defense. 
PAP depurinates Vif RNA, which inhibits its translation. Decreased levels of Vif correlate with 
increased levels of A3G. A3G gets incorporated into budding viral particles and upon infection 
of susceptible cells, the deaminase enzyme decreases accumulation of reverse transcripts and 
induces hypermutation of HIV-1 DNA. Therefore, inhibition of Vif by PAP upregulates levels of 
A3G and limits viral spread. 
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a preference of the RT enzyme for purine to purine substitutions or pyrimidine to pyrimidine 
substitutions (Preston et al. 1988). Since PAP can target different HIV-1 RNAs, the ability of the 
virus to develop resistance and escape the anti-viral activity of PAP would be minimized 
compared to drugs relying on inhibiting the activity of one specific viral enzyme. In addition, the 
very A-rich nature of the HIV genome (35% A) (van der Kuyl and Berkhout 2012), combined 
with the RT nucleotide misincorporation bias would minimize the emergence of PAP resistance. 
 
4.8 Conclusions and future directions 
Inhibition of Vif by PAP could explain the observed reduction in infectivity of HIV-1 
virions; however it does not explain the overall decrease in virus particle release, as the absence 
of Vif does not affect the amount of viral particles produced. Previous study showing inhibition 
of Rev activity suggested other HIV-1 RNAs can be targeted for depurination, as overexpression 
of Rev restored the 9-kb and 4-kb mRNAs to the cytosol, but did not recover viral protein 
expression (Zhabokritsky et al. 2014). Therefore, primer extension to detect depurinations in gag 
and pol ORFs should be performed to determine if the 9-kb and 4-kb RNAs can also be targeted 
by PAP.  
In addition, knowing how these RNAs are selected as targets for depurination would aid 
in our understanding of the antiviral activity of PAP. Previously, it has been shown that PAP is 
located in the cytosol in HEK293T cells (Mansouri et al. 2009); however, it is unknown whether 
PAP localizes to specific cytosolic foci such as P-bodies that are associated with viral infections. 
It would be interesting to see if HIV-1 RNAs and PAP co-localize in specific sub-cellular 
compartments. In addition, little is known about what cellular proteins interact with PAP. 
Binding of PAP to host factors could allow recruitment of PAP to viral RNAs. Therefore, 
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performing co-immunoprecipitation experiments to identify binding interactions could reveal 
potential cellular proteins involved in PAP anti-viral activity. 
Next, my data show that transient expression of PAP decreases infectivity of HIV-1 
particles which was attributed to increased A3G levels. In order to further support this, 
infectivity studies with HeLa cells not expressing A3G should be performed. Determining the 
infectivity of HIV-1 virions released from HeLa cells would also test whether in the absence of 
A3G, the infectivity of viral particles is increased due to activation of MAPK pathways as seen 
in HEK293T cells (Mansouri et al. 2012). In addition, studies in other cell lines, including T-cell 
lines endogenously expressing A3G, would be beneficial as it would provide more suitable 
model to study HIV-1 infection. Therefore, multiple factors contribute to the observed infectivity 
of HIV-1 virions in the presence of PAP and differential expression of host factors in cell lines 
can cause variable results.   
In the current study, I looked at transient expression of PAP and its effect on A3G-
mediated immune defense. It would be beneficial to look at the effect of PAP in a producer cell 
line expressing A3G on virus propagation over a longer time period. Determination of virus 
production over a longer time period could show if PAP is efficient at restricting production of 
infectious viruses. In addition, long-term study could also reveal whether PAP resistance is 
acquired with time and therefore determine the effectiveness of PAP as a biotherapeutic agent 
against HIV-1.    
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